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When things go wrong, as they sometimes will, 
When the road you’re trudging seems all uphill, 
When the funds are low and the debts are high, 
And you want to smile, but you have to sigh, 
When all is pressing you down a bit, 
Rest if you must, but don’t you quit. 
 
Success is failure turned inside out, 
The silver tint on the clouds of doubt, 
And you can never tell how close you are, 
It may be near when it seems far. 
 
So stick to the fight when you’re hardest hit, 
It’s when things go wrong that you must not quit. 
- J. G. Whittier 
 
 
 
 
“All the pieces will fit together” 
- Deno Fabbre 
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1. INTRODUCTION 
 
Pain is described as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage”. This definition was promulgated by 
the International Association for the Study of Pain (IASP) and it is in constant updating since its first 
publication (Merskey, 1979). Pain is always subjective. Each individual learns the application of the 
word through experiences related to injury in early life. It is unquestionably a sensation in a part or 
more parts of the body and it is always unpleasant and, therefore, it is also an emotional experience. 
Pain motivates the individual to withdraw from damaging situations, to protect a damaged body part 
while it heals, and to avoid similar experiences in the future. The inability to communicate verbally 
does not negate the possibility that an individual is experiencing pain and is in need of appropriate 
pain-relieving treatment. 
Pain should not be confused with nociception (Loeser and Treede, 2008). Nociception refers to the 
peripheral and central nervous system (CNS) processing of information about the internal or external 
environment, as generated by the activation of nociceptors. Typically, noxious stimuli, including 
tissue injury, activate nociceptors that are present in peripheral structures and that transmit 
information to the spinal cord dorsal horn or its trigeminal homologue, the nucleus caudalis. From 
there, the information continues to the brainstem and ultimately the cerebral cortex, where the 
perception of pain is generated (Fig 1). Hence, pain is a product of higher brain center processing and 
it is defined as a subjective experience that arguably exists only in the person that feels it (first-person 
perspective). Nociception is defined as observable activity in the nervous system in response to an 
adequate stimulus (third-person perspective) (Davis et al., 2017). The distinction between nociception 
and pain is also important for behavioural studies in which an understanding of pain mechanisms is 
the ultimate goal. Many behavioural tests involve assessment of reflex responses to noxious stimuli, 
typically applied at threshold or just suprathreshold intensities to incite a brief withdrawal of the tail 
or paw. These are principally tests of nociceptive processing because stimulus duration is limited by 
the animal’s response. On the other hand, the endpoints of more complex behaviours are presumed 
to involve supraspinal areas of the brain and as such are tests of both nociception and pain. 
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Fig 1. Anatomical distribution of nociception and pain. This figure schematizes the major neuroanatomical 
structures that differentiate nociception and pain, an understanding of which is essential for studies in which the 
animals may experience pain. Nociception refers to the process through which information about peripheral stimuli 
is transmitted by primary afferent nociceptors to the spinal cord, brainstem, thalamus, and subcortical structures. In 
contrast, the experience of pain can result only when there is activity of thalamocortical networks (represented in 
the dark shaded box at the top) that process the information conveyed by pathways of nociception. The magnitude 
of pain is determined to a great extent by the strength of descending inhibitory and facilitatory controls (in the lighter 
shaded boxes) that originate throughout the neuraxis and regulate the processing of ascending nociceptive messages 
[Figure adapted from (National Research Council Committee, 2009)]. 
 
Pain can be classified according to its location (e.g. visceral, joint or back pain...), to the clinical 
context (e.g. postsurgical, malignancy related, psychogenic...), to its intensity (mild, moderate, 
severe), and all of these categories sometimes overlap. However, the first, and probably the most 
intuitive, classification of pain was based on its duration: a pain sensation that lasts for less than 30 
days is defined as acute pain. It has a protective role, acts as an alarm for the organism and it is 
essential for survival. Chronic pain, instead, has been recognized as pain that persists past normal 
healing time (Bonica, 1953) and hence lacks the acute warning function of physiological nociception 
(Treede, 2011). Usually pain is regarded as chronic when it lasts or recurs for more than 3 to 6 months 
(Merskey, 1994). Chronic pain is a frequent condition, affecting an estimated 20% of people 
worldwide (Breivik et al., 2006; Goldberg and McGee, 2011; Treede et al., 2015) and accounting for 
15% to 20% of physician visits (Koleva et al., 2005). Chronic pain should receive greater attention 
as a global health priority because adequate pain treatment is a human right, and it is the duty of any 
health care system to provide it (Goldberg and McGee, 2011). 
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1.1 Neuropathic pain 
Neuropathic pain elicited by damage to or dysfunction of the sensory nervous system severely affects 
quality of life and is associated with a high economic cost for both the individual and society (Attal 
et al., 2011; Finnerup et al., 2015). The symptoms of neuropathic pain are sensory hypersensitivity 
defined by spontaneous pain, hyperalgesia, and allodynia (Jensen et al., 2011; Jensen and Finnerup, 
2014) resistant to standard analgesics (Finnerup et al., 2010). Hyperalgesia is defined as an 
abnormally increased sensitivity to pain, whereas allodynia is a painful sensation caused by innocuous 
stimuli like a light touch. 
Neuropathic pain can be caused by not only physical lesions (e.g., traumatic nerve injury and spinal 
cord injury) but also other reasons, such as diabetes, chemotherapy, and viral infection (Baron et al., 
2010). It is difficult to treat all types of hypersensitivity with currently available medications, and 
many patients with neuropathic pain do not receive appropriate treatment (Attal and Bouhassira, 
2015; Torrance et al., 2013). Thus, there is an urgent need for evidence-based development of novel 
pharmacotherapies for neuropathic pain. 
Growing evidence suggests that neuropathic pain induced by nerve damage is caused by a process of 
chronic inflammation. Upon nerve injury, damaged cells secrete pro-inflammatory molecules that 
activate cells in the surrounding tissue and recruit circulating leukocytes to the site of injury. Among 
these, the most abundant cell type is macrophages, which produce several key molecules involved in 
pain enhancement, including cytokines and chemokines. Given their central role in the regulation of 
peripheral sensitization, macrophage-derived cytokines and chemokines could be useful targets for 
the development of novel therapeutics. Inhibition of key pro-inflammatory cytokines and chemokines 
prevents neuroinflammation and neuropathic pain. In the following sections, the contribution of 
immune system in the onset and maintenance of neuropathic pain will be discussed more in detail. 
 
1.1.1 Pathophysiology of neuropathic pain: the role of immune system 
Recent studies have suggested that interactions between the nervous and immune systems trigger 
chronic neuroinflammation resulting in aberrant sensory processing and neuropathic pain (Calvo et 
al., 2012; Ji et al., 2016). Upon nerve injury, several cell types, including damaged neurons, 
demyelinated Schwann cells, and tissue-resident macrophages, produce soluble inflammatory 
cytokines, chemokines, and damage-associated molecular patterns (DAMPs) that activate 
surrounding cells (Thacker et al., 2007; Zhang et al., 2016) and recruit circulating leukocytes, such 
as monocytes/macrophages, neutrophils, and lymphocytes, into the site of injury (Kiguchi et al., 2012; 
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Ren and Dubner, 2010). Numerous pro-inflammatory cytokines (e.g., IL-1β and TNFα) and 
chemokines (e.g., CCL2, CCL3 and CCL4) are released by the infiltrating leukocytes, directly 
sensitize nociceptors, and alter the processing of nociceptive information by sensory neurons (Nicol 
et al., 1997; Oh et al., 2001). 
 
Peripheral and Central sensitization 
It is well known that pain sensation is processed by a discriminative set of primary afferent neurons 
(Basbaum et al., 2009; Todd, 2010). Unmyelinated C-fibers and thinly myelinated Aδ fibers act as 
nociceptors, while myelinated Aβ fibers are tactile sensors (Dubin and Patapoutian, 2010). Noxious 
stimuli such as heat, cold, pressure, and chemicals are converted to electrical activity by distinct 
cation channels (e.g., transient receptor potential (TRP) channels and sodium channels) that elicit 
action potentials (Moran et al., 2011; Waxman and Zamponi, 2014). Primary afferent neurons 
producing glutamate or neuropeptides transmit peripheral information to secondary neurons in the 
spinal dorsal horn (Basbaum et al., 2009; Todd, 2010). During neuropathic pain, the expression and 
sensitivity of these channels become dysregulated and elicit ectopic activity of nociceptive DRG 
neurons (Dib-Hajj et al., 2009; Liu and Wood, 2011). Despite the complexity of the underlying 
mechanisms, the close relationship between ectopic activity and pro-inflammatory mediators has 
been noted in several studies (Pinho-Ribeiro et al., 2017; Xanthos and Sandkuhler, 2014). Because 
many nociceptive DRG neurons express pro-inflammatory cytokine and chemokine receptors that are 
upregulated after nerve injury, pro-inflammatory molecules can directly sensitize nociceptors, such 
as TRP channels, in C-fibers leading to hypersensitivity. For example, IL-1β, TNFα, IL-6, CCL2, and 
CCL3 are well-known enhancers of nociceptor activity (Nicol et al., 1997; Oh et al., 2001). Thus, 
long-lasting neuroinflammation resulting from upregulation of inflammatory molecules by damaged 
tissue and infiltrating leukocytes can contribute to the ectopic discharge of sensory neurons, resulting 
in peripheral sensitization. Prolonged abnormal transmission of pain signalling into the spinal dorsal 
horn due to peripheral sensitization triggers central sensitization (Haroutounian et al., 2014; von Hehn 
et al., 2012), characterized by increased excitability of pain-processing neurons and activation of glial 
cells (microglia and astrocytes) (Grace et al., 2014; Ji et al., 2014). These glial cells have been the 
focus of increasing attention in the past few decades, and their critical contribution to spinal 
neuroinflammation underlying neuropathic pain is now well characterized (McMahon et al., 2005; 
Scholz and Woolf, 2007; Tsuda et al., 2005). Microglia and astrocytes are activated by several 
neurotransmitters derived from primary afferent neurons, such as cytokines, chemokines, and 
nucleotides. Activation of glial cells induces a variety of pro-inflammatory factors that directly or 
indirectly sensitize pain-processing neurons in the spinal dorsal horn (Calvo et al., 2012; Grace et al., 
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2014; Ji et al., 2014). Similar to the peripheral response, typical inflammatory cytokines (IL-1β, 
TNFα, IL-6), chemokines (CCL2 and CCL3), and growth factors are upregulated in the dorsal horn 
after nerve injury, and inhibition of these molecules reverses neuropathic pain (Kiguchi et al., 2010; 
Thacker et al., 2009). These pain-facilitating molecules function to sensitize ionotropic glutamate 
receptors such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and N-
methyl-D-aspartate (NMDA) receptors (Basbaum et al., 2009; Grace et al., 2014). Because AMPA 
and NMDA receptors play central roles in pain processing in the spinal cord, modulation of their 
sensitivity by pro-inflammatory mediators derived from activated glial cells is also important for the 
pathogenesis of neuropathic pain (Fig. 2).  
 
 
Fig 2. Generation of neuropathic pain by macrophage-driven inflammation in the peripheral nervous system. 
After nerve injury, activated resident cells (Schwann cells and macrophages) produce soluble factors such as 
damage-associated molecular patterns (DAMPs) that activate nearby cells and recruit circulating leukocytes 
(macrophages, neutrophils, and lymphocytes) to the site of injury. Macrophages are the most abundant infiltrating 
leukocyte population and are thought to play a central role in regulating peripheral neuroinflammation. Tissue-
resident and infiltrating leukocytes communicate through the release of pro-inflammatory mediators such as 
cytokines and chemokines, which convey nociceptive information to dorsal root ganglia (DRG) neurons. Persistent 
ectopic activity of DRG neurons induces central sensitization characterized by the enhanced activity of pain 
processing neurons and the activation of microglia and astrocytes. Pharmacological targeting of macrophages or 
macrophage-derived pro-inflammatory molecules by nicotinic acetylcholine receptor (nAChR) ligands, Th2 
cytokines, and inhibitors of cytokines and chemokines can suppress macrophage-driven neuroinflammation after 
nerve injury. The reduction in neuroinflammation improves both peripheral and central sensitization and alleviates 
intractable neuropathic pain [Source: (Kiguchi et al., 2017)]. 
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1.1.2 Animal models of neuropathic pain 
The study of neuropathic pain mechanisms is largely based on animal models (Calvo et al., 2012; Sah 
et al., 2003; Ueda, 2006), which date back to the late 19th century (Von Frey, 1896). Although these 
models have weak points, they have immensely contributed to our understanding of the key 
components of neuropathic pain development. Animal models of pain are designed to mimic distinct 
clinical diseases to better evaluate underlying mechanisms and potential treatments. Outcome 
measures are designed to evaluate multiple parts of the pain experience including reflexive 
hyperalgesia measures, sensory and affective dimensions of pain and impact of pain on function and 
quality of life. 
Peripheral nerves have been targeted in many well characterized models of neuropathic pain. Direct 
nerve injury models include I) ligating or transecting the spinal nerves (spinal nerve ligation, SNL, 
or spinal nerve transection SNT), II) ligating or lesioning the sciatic nerve (chronic constriction 
injury, CCI), and III) ligating distal branches (peroneal, tibial) of the sciatic nerve (spared nerve 
injury, SNI) (Bennett and Xie, 1988; Decosterd and Woolf, 2000; Kim and Chung, 1992). The 
principles of these methods may be applied to nerves other than the sciatic, such as orofacial nerves 
(Vos et al., 1994). The behavioural phenotypes are essentially indistinguishable between these 
different peripheral nerve models, with decreased withdrawal thresholds to mechanical and thermal 
stimuli and spontaneous guarding behaviour of affected limbs (Takaishi et al., 1996). 
The existing models, however, are often criticized to not reflect clinical pain characteristics (Cobos 
et al., 2012), which are mostly of spontaneous nature. Persistent or chronic pain is experienced by 
day and night. It affects sociability and often the ability for voluntary behavioural tasks. Pain increases 
the rate, frequency, or intensity of some behaviors (eg, withdrawal responses) and suppresses other 
behaviors (eg, feeding). These aspects are severely under investigated in rodents and difficult to 
assess. While patients can describe their pain orally, most rodent studies rely on short-duration 
stimulus-evoked unilateral hind paw measurements. It is commonly agreed that we need to analyze 
new parameters that may reflect impairments in the quality of life (Barrot, 2012).  
Neuropathic pain models described above induce changes also in non-reflexive (spontaneous) pain, 
such as vocalization (Kurejova et al., 2010), change in spontaneous motor activity (Gregoire et al., 
2012), conditioned place preference (CPP), escape avoidance (PEAP) (LaGraize et al., 2004) and 
social behaviour such as dominance (Monassi et al., 2003). However, these tests are subject of 
controversy and do not work consistently across laboratories (Tappe-Theodor and Kuner, 2014). 
There are numerous reasons for this, including the lack of standardization. 
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Over the past two decades, numerous novel ‘pain targets’ including receptors, ion-channels and 
enzymes have been identified and implicated in the pathophysiology of chronic pain. However, most 
compounds that modulate these targets failed to show analgesic efficacy in proof-of-concept human 
clinical trials, despite promising preclinical data. For this reason, the research of novel drugs for the 
treatment of neuropathic pain have to consider the efficacy of each compound on pain-suppressed 
and non-evoked pain behaviours rather than only pain-elicited behaviours. This will provide means 
for distinguish true analgesics and will bring us closer to a better bench-to-bedside translation.  
 
 
Fig 3. Experimental models of neuropathic pain. [Source (Challa, 2015)] 
 
 
1.1.2.1 Chronic Constriction Injury (CCI) 
Sciatic nerve CCI resembles human neuropathy resulting from trauma of peripheral nerves, with some 
functional preservation of the innervation (nerve entrapment or compression) (Colleoni and 
Sacerdote, 2010). The CCI model was first described in 1988 (Bennett and Xie, 1988) and the surgical 
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procedure consists of the loose ligation of the sciatic nerve at mid-thigh level with not absorbable 
sutures. An inflammatory reaction develops in response to the surgery and consequentially a loss of 
most A-fibres and some C-fibres, but few cell bodies. This is associated with spontaneous pain-related 
behaviour, allodynia and hyperalgesia. It has been demonstrated that anti-inflammatory treatments of 
CCI animals decreases the associated thermal hyperalgesia and so it is speculated that there is a 
significant inflammatory component in the development of the painful neuropathy (Bridges et al., 
2001). 
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1.2 ADENOSINE PATHWAY: SAFER PAIN-RELIEVING PROSPECTS 
 
1.2.1 Acting on adenosine signalling to modulate inflammation and pain 
Adenosine, an endogenous purine nucleoside composed of adenine attached to a ribose, is 
constitutively present in the extracellular space (ES) and it is an important signalling molecule which 
regulates several biological functions. Under normal metabolic conditions, concentrations of 
adenosine in ES are definitively low (in the low-micromolar to high-nanomolar range) and the 
majority of it is taken up into cells and rapidly incorporated into ATP stores or deaminated by 
adenosine deaminase (Latini and Pedata, 2001). The occurrence of pathological events promotes a 
massive release of ATP from damaged or dying cells, and its consequent accumulation in ES. ATP 
released provides qualitative and quantitative information about the injury, triggering a series of 
proinflammatory responses including “danger” and “find me” signals for phagocytes to migrate to 
damaged tissue (Dosch et al., 2018; Trautmann, 2009). Extracellular ATP metabolism is mediated by 
a cascade of membrane-bound nucleotidases: CD39 (ecto-nucleoside triphosphate 
diphosphohydrolase 1, E-NTPDase 1) converts ATP into AMP and then CD73 (ecto-5’-nucleotidase, 
Ecto5’NTase) dephosphorylates AMP into adenosine (Hasko et al., 2008). In this way, in response to 
stress or injury, the extracellular concentration of adenosine can increase up to 1000-fold (Ballarin et 
al., 1991) and this drives a shift from an ATP-driven proinflammatory environment to an anti-
inflammatory milieu induced by adenosine (Beavis et al., 2012). Adenosine elicites responses in 
various cell types of the central nervous system including neurons, astrocytes, and microglia 
(Fredholm et al., 2011) and in general promotes, also at peripheral level, a depressive action on 
immune cells activity. In particular, it has been shown that adenosine enhances anti-inflammatory 
activity of Tregs and, at the same time, reduces the proinflammatory activity of effector T cells by 
inducing their differentiation in Tregs. By employing these two different mechanisms, the beneficial 
effects of adenosine result quickly effective and persistent (Ohta and Sitkovsky, 2014) (Fig 4). 
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Fig 4 Adenosine promotes a depressive action on immune cells activity and exerts a potent anti-inflammatory 
effect. ATP released into ES from stressed or damage cells acts as an important signalling molecule. Adenosine is 
the final bioactive product of ATP breakdown. The increase of adenosine concentrations in ES is related to the 
activation of an auto regulatory loop, the function of which is to modulate immune system and inflammatory 
response. 
 
Adenosine acts through a family of four G protein-coupled adenosine receptors (ARs): A1, A2A, A2B 
and A3 each of which has a unique pharmacological profile, tissue distribution and effector coupling. 
Among the human ARs, the most similar are the A1 and A3 ARs (49% sequence similarity) and the 
A2A and A2B ARs (59% sequence similarity). ARs have traditionally been classified based on their 
differential coupling to Gα subunit: A1 and A3 are coupled to Gi/Gq proteins while A2A and A2B are 
coupled to Gs (Fredholm et al., 2011). Therefore, activation of the A2A and A2B ARs subtypes 
increases cyclic AMP production, resulting in activation of protein kinase A (PKA) and 
phosphorylation of the cyclic AMP response element binding protein (CREB). In contrast, activation 
of the A1 and A3 ARs inhibits cyclic AMP production and decreases PKA activity and CREB 
phosphorylation (Cunha, 2001; Jacobson and Gao, 2006). In some cases, the A1AR increases 
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phospholipase C (PLC) activity through a pertussis toxin-sensitive G protein. The A1AR can also 
directly couple to and inhibit cardiac K+ channels and types Q, N and P voltage sensitive Ca2+ 
channels. In turn, the A3AR can regulate the activity of PLC via a pertussis toxin-sensitive G protein 
or by direct coupling to Gq protein (Jacobson and Gao, 2006; Sheth et al., 2014).  All four subtypes 
of ARs can couple to mitogen-activated protein kinase (MAPK), giving them a role in cell growth, 
survival, death and differentiation (Fig 5). Phosphorylation and subsequent desensitization of ARs 
have been studied for all four subtypes. The rapidity of the desensitization depends on the subtype, 
with the A3AR being more rapidly desensitized than the other subtypes (Olah and Stiles, 2000). 
 
 
 
Fig 5: Adenosine receptor signalling pathway. Adenosine initiates its biological effects via four receptor subtypes, 
each of which has a unique pharmacological profile and effector coupling. The importance of these receptors in the 
regulation of a great variety of physiological functions makes them promising therapeutic targets in a wide range of 
conditions. DAG, diacylglycerol; IP3, inositol 1,4,5-trisphospate; PI3K phosphatidylinositol 3-kinase; PIP2, 
phosphatidylinositol-4,5-bisphosphate; PLD, phospholipase; NF-kB, nuclear factor-kB (Jacobson and Gao, 2006). 
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Because of ubiquitous distribution of ARs throughout the organism, adenosine pathway has been 
implicated in several biological functions including cardiac rhythm and circulation, angiogenesis, 
synaptic plasticity, inflammatory diseases and neurodegenerative disorders (de Mendonca and 
Ribeiro, 1997; Fredholm, 2007; Hasko et al., 2008; Liu et al., 2010). Adenosine is also reported to 
provide a potent and long-lasting pain relief in both preclinical animal models and human subject 
studies (Hayashida et al., 2005; Zylka, 2011).  
A role for adenosine in antinociception was first identified in the 1970s and then elaborated in the 
1980s with systemic and spinal administration of those compounds that, at the time, were considered 
selective agonists. These first studies emphasized the role of A1 and A2A ARs (the only subtypes 
known at that time) and since then up to the least 10 years research has been focused on the use of 
A1AR or A2AAR agonists for the treatment of pain of different etiologies. It has been demonstrated, 
in cultured cells and mouse DRG, that sustained activation of A1AR leads to depletion of 
phosphatidylinositol 4,5-biphosphate (PIP2) resulting in an inhibition of thermosensation through 
TRPV1 and a reduction of thermal hyperalgesia and mechanical allodynia induced by inflammation 
or nerve injury (Sowa et al., 2010). A2AAR agonists were found to enduringly reverse allodynia and 
hyperalgesia caused by nerve injury in rats (for up to four weeks after a single intrathecal injection) 
(Loram et al., 2009).  
However, targeting adenosine endogenous pathway using A1AR or A2AAR agonists failed to yield a 
viable therapeutic approach: although these agonists are in clinical development for neuropathic pain, 
their use is restricted to local delivery, since a systemic administration would risk cardiovascular side 
effects from the activation of A1AR expressed in conducting tissues or A2AAR in vascular smooth 
muscle (Boison, 2013; Jacobson et al., 2011; Taliani et al., 2010; Zylka, 2011). 
 
1.2.2 A3 Adenosine Receptor (A3AR): a novel target for the treatment of neuropathic 
pain 
Although the basic science suggests that selective AR modulators have promise for numerous 
therapeutic applications, in practice this goal has been elusive. One reason for this is the ubiquity of 
ARs and the possibility of side effects. In addition, species differences in the affinity of putatively 
selective ligands complicate preclinical testing in animal models. However, there has been an impetus 
towards novel clinical targets, in part as a result of the discovery of the A3AR subtype in the early 
1990s and of the elucidation of new roles for adenosine.  
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The generation of cDNA for A3AR has allowed the demonstration of the wide expression of this 
receptor subtype throughout the organism: its mRNA was found expressed in the testis, lung, kidneys, 
placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, proximal colon, and eye (Burnett et al., 
2010; Dixon et al., 1996; Linden, 1994; Salvatore et al., 1993) also if marked differences in expression 
levels do exist within and between species. Looking at the structures involved in nociception and 
pain, A3AR expression has been reported in thalamus, hypothalamus and amygdala (Dixon et al., 
1996; Yaar et al., 2002) and electrophysiologic and biochemical evidence suggests the presence of 
A3AR also in hippocampus (Lopes et al., 2003) and cortex (Brand et al., 2001). The presence of 
A3AR in peripheral sensory neurons (Ru et al., 2011) and at motor nerve terminals (Cinalli et al., 
2013) was recently demonstrated. At cellular level, A3AR expression has been observed in microglia 
and astrocytes, the resident immune cells of the CNS (Gessi et al., 2013; Ohsawa et al., 2012). It is 
worth nothing that A3AR has been found expressed in a variety of immune cells and its activation is 
involved in the physiopathological regulation of inflammatory and immune processes mediated by 
adenosine (Antonioli et al., 2010; Hasko and Cronstein, 2013). Human eosinophils were the first cells 
in which A3AR was detected (Kohno et al., 1996), then followed by neutrophils (Bouma et al., 1997; 
Corriden et al., 2013), macrophages (McWhinney et al., 1996), monocytes (Broussas et al., 2002), 
dendritic cells (Fossetta et al., 2003), lymphocytes (Gessi et al., 2004), bone marrow cells and lymph 
nodes (Bar-Yehuda et al., 2011). 
Since from its discovery A3AR presented a twofold nature: its activation appeared to be protective 
and harmful, pro and anti-inflammatory, pro and anti-tumoral, depending on the system investigated 
and the different pathophysiological conditions considered. This was due to the fact that agonists used 
at that time were not selective, thus they activated also other AR subtypes which mediate pro-
inflammatory responses. However, during the last decade of research, several studies have been 
carried out to clarify the role of A3AR agonism and antagonism in different pathologies. A3AR 
modulation has been demonstrated to be a winning strategy in the treatment of rheumatoid arthritis 
(Baharav et al., 2005; Ochaion et al., 2006), inflammatory bowel diseases (Antonioli et al., 2010; 
Guzman et al., 2006), uveitis (Bar-Yehuda et al., 2011), myocardial and skeletal muscle ischemia 
(Wan et al., 2008; Zheng et al., 2007) and cancer (Cohen et al., 2011; Fishman et al., 2003; Fishman 
et al., 2001). In addition to its role as a therapeutic target, A3AR is now recognized also as a biological 
marker given its overexpression in inflammatory and cancer cells, compared with low levels found 
in healthy cells (Fishman et al., 2006; Gessi et al., 2004; Madi et al., 2004; Morello et al., 2008; 
Ochaion et al., 2009). An important aspect to underlie is that, in contrast to A1AR and A2AAR 
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agonists, the activation of the A3AR in humans by potent, selective, and orally bioavailable A3AR 
agonists is not associated with cardiac or hemodynamic effects (Silverman et al., 2008). 
Endogenous adenosine signalling through A3AR has also been demonstrated to be neuroprotective 
(Boison et al., 2010; Fishman et al., 2012) and some studies, especially in the last few years, have 
deeply investigated the role of this receptor in pain, using different animal models. One of the first 
studies carried out by Yoon and colleagues, has examined the effects of A3AR agonists in mice, using 
formalin test (Yoon et al., 2005). In this work, intrathecal delivery of A3AR agonist (IB-MECA) 
attenuated the inflammatory component, phase 2 but not phase 1, of the formalin test, demonstrating 
that A3AR is responsible for the modulation of nociceptive mechanisms underlying central 
sensitization. In 2012 Dr Salvemini’s group has demonstrated for the first time that activation of the 
A3AR reverses established mechano-allodynia in mice which underwent chronic sciatic nerve ligation 
(CCI) and blocks the development of chemotherapy-induced peripheral neuropathy (CIPN) in rats 
following the administration of widely used chemotherapeutic agents (bortezomib, oxaliplatin and 
paclitaxel) with distinct antitumor mechanism of action (Chen et al., 2012). Is noteworthy that the 
analgesic effects of A3AR agonists are naloxone insensitive, and thus are not opioid receptor 
mediated, and are ≥1.6-fold more efficacious than morphine and >5-fold more potent. These findings 
provided the scientific rationale and pharmacological basis for considering a therapeutic development 
of A3AR agonists for the treatment of chronic pain. Other studies conducted by the same group 
provided new insights in the role of A3AR modulation in CIPN. In particular, it has been shown that 
A3AR agonists block the development of paclitaxel-induced neuropathic pain by inhibiting the 
activation of spinal NADPH oxidase.  
This leads to the blockade of redox-dependent signalling pathways (NFκB and MAPK) and a decrease 
of glial-associated neuroexcitatory/pro-inflammatory cytokine production (TNF-α and IL-1β). At the 
same time, A3AR agonists restores glutamatergic homeostasis by blocking the nitration/inactivation 
of glutamate transporter GLT-1 and glutamine synthetase (Fig 6A). Treatment with the selective 
A3AR agonists also increases the formation of the neuroprotective/anti-inflammatory cytokine, IL-
10 (Janes et al., 2014). Afterwards, it has been demonstrated that, in CIPN model, A3AR agonists 
treatment also prevent astrocytic hyperactivation in the spinal cord, which is responsible for the 
maintenance of chronic pain induced by chemotherapeutic drugs (Janes et al., 2015).  
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Fig 6 Proposed schematic representation of mechanisms underlying A3AR agonists’ beneficial effects in CIPN 
(A) and CCI (B) model. A) Chemotherapy (paclitaxel)-induced neuropathic pain is associated with increased 
NADPH oxidase activity within the spinal cord contributing to enhanced peroxynitrite (PN) production. PN induces 
the nitration/inactivation of glutamate transporter 1 (GLT-1) and glutamine synthetase (GS) and the activation of 
redox-dependent signaling pathways (NFκB and MAPK) leading to a surge in glial-associated pro-inflammatory 
cytokine production (TNF-α and IL-1β). Treatment with the selective A3AR agonist not only inhibits paclitaxel-
induced pain and the associated spinal events, it also increases the formation of the neuroprotective/anti-
inflammatory cytokine, IL-10. (Janes et al., 2014) B) Stimulation of Periacqueductal Gray (PAG) by different brain 
regions (not shown) initiate descending pain inhibition. PAG communicates both directly with the Rostro Ventral 
Medulla (RVM) and through the Locus Coreuleus (LC) to send descending noradrenergic (NE) and serotoninergic 
(5-HT) inhibitory projections to the spinal cord (Ossipov et al., 2014). A3AR activation in the RVM engages 
bulbospinal inhibitory circuits to suppress spinal nociception. At the same time A3AR stimulation at spinal cord 
level directly inhibits the excitability of spinal wide dynamic range (WDR) neurons (Little et al., 2015). 
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Significant progress has been achieved also in understanding the contribution of A3AR stimulation 
in alleviating CCI-induced neuropathic pain. Administration of A3AR agonists following sciatic 
nerve ligation totally abrogate mechano-allodynia without promoting analgesic tolerance or inherent 
reward. Further examination revealed that A3AR activation reduced spinal cord pain processing by 
decreasing the excitability of spinal wide dynamic range neurons and producing supraspinal 
inhibition of spinal nociception through activation of serotonergic and noradrenergic bulbospinal 
circuits (Little et al., 2015) (Fig 6B).  
Using the same animal model, it has been also demonstrated that the analgesic effects of A3AR 
agonists are due also to the modulation of GABA activity (Ford et al., 2015). The deregulation of 
GABA signaling in pathophysiological pain states is well established: GABA signaling can be 
hampered by a reduction in extracellular GABA synthesis by GAD65 and enhanced extracellular 
GABA reuptake via the GABA transporter, GAT-1. In neuropathic pain, GABAAR-mediated 
signaling can be further disrupted by the loss of the KCC2 chloride anion gradient. Ford and 
colleagues have shown how A3AR selective agonists restore the function of proteins involved in the 
regulation of GABA bioavailability as well as KCC2 function in CCI animals. 
It has been reported that peripheral nerve injury activated also convergent nociceptive inputs from 
uninjured afferents in the spinal dorsal horn and that microglial activation induced such anomalous 
inputs (Terayama et al., 2015; Yamamoto et al., 2015). In a recent work, it has been demonstrated 
that A3AR selective agonists are able to suppress enhanced microglial activation and thus 
anomalous convergence of nociceptive inputs in the spinal dorsal horn attenuating neuropathic pain 
states (Terayama et al., 2018). Engaging the A3AR mechanism did not alter nociceptive thresholds 
in non-neuropathy animals (Little et al., 2015). 
Although relevant findings have already been reported (Ford et al., 2015; Wahlman et al., 2018; 
Yan et al., 2016), molecular mechanisms underlying A3AR agonism remain still largely 
unexplored. Contrary to the very first studies, which reported a pro-nociceptive role (in large part 
due to the use of nonselective agonists), is now widely proved that targeting A3AR induce a robust 
anti-inflammatory and long lasting antinociceptive effects (Janes et al., 2016).  
Thus, A3 receptor stimulation appears to be a safe and successful strategy for exploiting the potent 
analgesic action of adenosine to provide a breakthrough non-opioid treatment for patients suffering 
from chronic pain. 
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1.2.2.1 A3AR highly selective agonists 
The development of potent and selective synthetic agonists and antagonists of ARs has been the 
subject of medicinal chemistry research for more than three decades. As mentioned above, A1 and 
A2a receptor agonists resulted to have a restricted therapeutic use, whereas there has been a growing 
interest in the research of novel A3AR agonists, also due to their beneficial effects against chronic 
neuropathic pain. 
The relationship between the structure of adenosine and its biological activity on the A3 receptor has 
been extensively explored, and modifications of the adenosine structure have been initially focused 
on the adenine C2 and N
6 positions and on the ribose moiety. 
Adenosine derivatives bearing an N6-(3-iodobenzyl) group reported to be 2-fold more selective for 
A3 vs A1 or A2a receptors. The introduction of a 5’-methyluronamide modification in combination 
with N6-substitution has generated N6-(3-iodobenzyl)-5‘-N-methylcarboxamidoadenosine (IB-
MECA or CF101) (Fig 7b), a compound which is 50-fold more selective for A3 vs either A1 or A2a 
receptor (Li et al., 1998; Olah et al., 1994; van Galen et al., 1994). Later on, the effects of 2-
substituition in combination with modification at N6- and 5’- position were explored. 2-chloro-N6-
(3-iodobenzyl)-adenosine-5'-Nmethyluronamide (Cl-IB-MECA) was the first potent and highly 
selective A3AR agonist reported (Kim et al., 1994). The introduction of a Cl was observed to 
incredibly enhance the selectivity for A3AR subtype: this compound is 2500- and 1400-fold more 
selective for A3 vs A1 and A2a receptors respectively. These prototypical agonists are advancing to 
phase II and III clinical trials for psoriasis, rheumatoid arthritis and cancer (David et al., 2016; 
Stemmer et al., 2013). The replacement of the flexible tetrahydrofuryl ring with a conformationally 
constrained bicyclo[3.1.0]hexane (methanocarba) ring system, which enforces a North (N)-envelope 
conformation, provided an highly optimized structures for specific A3AR recognition (Jacobson et 
al., 2000) (Fig 7c). This modified compound, as well as IB-MECA and Cl-IB-MECA, were shown to 
be active in reducing or preventing the development of CCI- and chemotherapy-induced neuropathic 
pain in mice and rats (Chen et al., 2012). (N)-Methanocarba (bicyclo[3.1.0]hexane)-adenosine 
derivatives were subsequently probed for sites of charged sulfonate substitution, to increase the 
solubility of these compounds, an important quality for good pharmacological tools (Paoletta et al., 
2013) (Fig 7d). A negatively charged sulfonate substitution of small molecules, indeed, is one means 
of excluding diffusion across biological membranes such as the blood brain barrier. Such potent and 
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selective A3AR agonists would be useful in delineating in vivo effects in the CNS from those in the 
periphery, depending on the route of administration. 
During the last 5 years, research focused on further expand the family of A3AR agonists for the 
treatment of chronic neuropathic pain. In particular, several modifications of ring structures appended 
to the 2-ethynyl group were studied, such as heterocyclic groups, aryl groups and cycloalkyl groups 
(Tosh et al., 2014). In vivo activities of these compounds were compared in correlation with their 
structure and some preferred candidates have been identified.  
 
 
Fig 7. Evolution of synthetic highly selective A3AR agonists. Chemical structures of typical adenosine derivatives 
as A3AR agonists [Figure adapted from (Paoletta et al., 2013; Tosh et al., 2015a; Tosh et al., 2015b).] 
 
 
Interestingly, it has been found that 2-(arylethynyl)adenine compounds were nanomolar full agonists 
of A3AR and, in particular, the highly selective (1S,2R,3S,4R,5S)-4-(6-((3-chlorobenzyl)amino)-2-
((3,4-difluorophenyl)ethynyl)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-
carboxamide (MRS5698) first became an important pharmacological tool for defining A3AR effects 
in a chronic neuropathic pain model (Tosh et al., 2012; Tosh et al., 2015b) (Fig 7e). Although the 
molecular weight is higher than generally preferred, MRS5698 displays good efficacy and 
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bioavailability. Similarly, it has been demonstrated that also 2-thienyl derivatives are some of the 
most efficacious analogues in vivo, and, among them, (1S,2R,3S,4R,5S)-4-(2-((5-Chlorothiophen-2-
yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-
carboxamide (MRS5980) appeared to be the leading candidate molecule for in vivo studies on chronic 
neuropathic pain (Fig 7f). It has a favourable balance of high and prolonged efficacy ( >3h ), predicted 
in vivo stability, very few off-target interactions and high hydro solubility. Moreover, physiochemical 
parameters of this compound were optimized to further increase its bioavailability. The ED50 value 
for MRS5980 at its peak effect following oral administration is 0.34 mg/kg (0.73 mol/kg; n=5) (Tosh 
et al., 2015a). Recently, more intensive in vivo and in vitro analysis have been conducted to better 
characterize MRS5980 pharmacological profile. Drug efficiency, toxicity, and metabolic elimination 
are the major properties determining whether a drug candidate can successfully enter clinical 
trials (Fang and Gonzalez, 2014). For this reason, Fang and colleagues have used metabolomics to 
evaluate the MRS5980-body metabolism and interactions, including the metabolic elimination of 
MRS5980, electrophilic reactivity and influence on lipid profiles of MRS5980 in the organism (Fang 
et al., 2015). 
 
A3AR agonists are more potent than currently used analgesics (gabapentin, amitriptyline, morphine) 
(Chen et al., 2012) and, so far, showed an excellent safety profile and efficacy for the treatment of 
inflammatory, ophthalmic and liver diseases. The novel concept of using these agonists, such as 
MRS5980, also for treating chronic neuropathic pain is very attractive. However, additional 
preclinical characterization is needed prior to a proposed clinical trial.  
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1.3 PROKINETICIN SYSTEM: A MULTIFUNCTIONAL FAMILY OF 
CHEMOKINES 
 
1.3.1 Cytokines and chemokines involvement in inflammation and pain perception: 
focusing on prokineticin system  
Immune and nervous system have evolved to provide regulation of physiological homeostasis and to 
protect against threats (Gonzalez et al., 2014). The role of immune system is to defend the organism 
against infections and injuries, whereas, the nervous system integrates all the biological functions and 
provides nearly instantaneous homeostatic control mechanisms by releasing neurotransmitters and 
other regulatory molecules (Chavan et al., 2017). Both systems have the capability to recall earlier 
challenges and events, mounting memory responses that anticipate and efficiently adapt to ever 
changing conditions. Nervous and immune cell functions rely on cell-to-cell contacts and on soluble 
molecules that act on proximal or distant target cells. These communication molecules include 
neuropeptides, neurotrophins, cytokines and chemokines (Ordovas-Montanes et al., 2015). Cytokines 
are small (5-30 kDa) active molecules produced by a broad range of cells including macrophages, 
lymphocytes, mast cells as well as endothelial cells, fibroblasts and various stromal cells. Cytokines 
are pleiotrophic secreted proteins that were originally characterized as immune modulators but have 
subsequently been found to mediate a diverse array of functions also in non-immune tissues, including 
the nervous system. The typical feature of most cytokines is a low or no constitutive production and 
a transient expression (they exert their effects at concentrations within the pico- nanomolar range) 
following the inducing stimuli. The term “cytokine” is derived from a combination of two Greek 
words: “cyto”, which means “cell” and “kinos” meaning “movement”, due to the observation of their 
capability to induce the migration of immune cells towards the sites of inflammation, infection and 
trauma. Cytokines, more in general, are involved in cell-to-cell communication: through both 
autocrine and paracrine signalling, they actually regulate multiple biological functions such as 
embryonic development, hematopoiesis, cell growth, differentiation and aging (Foster, 2001). 
Cytokines operate within a complex network and can act synergistically or antagonistically (Fig 8). 
Based on the functional profile of an immune response cytokines’ production is broadly orchestrated 
by T helper 1 cells (Th1) which generally mediate a pro-inflammatory cellular immune response, and 
T helper 2 cells (Th2) which, instead, enhance and anti-inflammatory and humoral immune reaction. 
Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interferon-γ (IFN-γ), 
Interleukin-1β (IL-1β), Interleukin-6 (IL-6), prime a Th1 response, enhancing the elimination of 
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intracellular pathogens. On the other hand, the anti-inflammatory cytokines such as Interleukin-4 (IL-
4) and Interleukin-10 (IL-10) drive the Th2 response, enabling phagocytosis of extracellular 
pathogens and debris, tissue repair and dampening the synthesis of pro-inflammatory cytokines 
(Kronfol and Remick, 2000).  
 
 
Fig 8. The overall effect of an inflammatory response is dictated by the balance between pro- and anti-
inflammatory mediators [source (Bagaitkar, 2014)]. 
 
Presently, more than 200 cytokines are recognized. As we said, this class include interferons, 
interleukins, lymphokines, tumour necrosis factors and chemokines. Chemokines (Chemoattractant 
cytokines), originally identified as regulators of peripheral immune cell trafficking, represent a unique 
class of neuromodulators that can regulate phenomena as diverse as development, neuroinflammation 
and synaptic transmission. Chemokines exert their biological effects through cell-surface receptors 
that belong to G protein–coupled receptors (GPCRs) family. The structure of these receptors is a 
single polypeptide chains of about 350 residues spanning 7 times the membrane, three intracellular 
and three extracellular hydrophilic loops, a short amino-terminal (N-terminal) extracellular domain 
and a serine/threonine-rich intracellular carboxyl-terminal (C-terminal) domain, important for 
receptor regulation. In the first two extracellular loops are present 2 of 4 conserved cysteine residues 
that allow the formation of the first disulphide bound required for the definition of the molecular 
structure, whereas, the second one is due to the bound between the N-terminal domain and the third 
extracellular loop structure (Bonecchi et al., 2009). Chemokine receptors activate various signalling 
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pathways, such as the Mitogen-Activated Protein Kinase (MAPK) pathway, the Phospholipase C 
(PLC) pathway resulting in Ca2+ influx, and the phosphatidyl inositol-3 kinase (PI3K) pathway 
(Bajetto et al., 2002; Cartier et al., 2005), leading to varied functional outcomes, including adhesion, 
polarization and chemotaxis. 
About twenty years ago, for the first time by Dr Melchiorri and Dr Negri group, a small peptide of 
77 amino acids was isolated from skin secretions of Bombina Variegata frog and called Bv8, to 
indicate its origin and its molecular weight of 8 KDa. Homologues of this protein were founded in 
spiders (atracotoxin-Hvf17) and snakes (Mamba Intestinal Toxin-1, MIT1) (Mollay et al., 1999). In 
particular, the amino acid sequence of Bv8 is very similar to MIT-1 since they share 58% of sequence 
identity (Negri et al., 2002). This observation suggested that similar proteins could be found also in 
other species, including mammals. Analysing cDNA libraries using functional cloning, it was 
possible to identify homologues of Bv8 in mice (Wechselberger et al., 1999) and in rats (Masuda et 
al., 2002). Later on, Li and colleagues identified two genomic sequences in human which gave origin 
to two proteins similar to Bv8, called Prokineticin 1 (PROK1) and Prokineticin 2 (PROK2) referring 
to their ability to contract guinea pig ileum in vitro (Li et al., 2001). During the same period, Ferrara 
and colleagues identified a protein able to induce proliferation, migration and fenestration of 
endothelial cells in testis ovary and adrenal glands (LeCouter and Ferrara, 2003; LeCouter et al., 
2003a). This protein was called endocrine-gland-derived vascular endothelial growth factor (EG-
VEGF) since its effects were similar to the ones induced by VEGF (LeCouter et al., 2001). Actually, 
EG-VEGF and PROK1 are the same protein.  
All these proteins share some structural characteristics (Fig 9): 
- Identical amino-terminal (N-terminal) sequence important for the biological activity and 
receptor recognition (alanine, valine, isoleucine, threonine, glycine and alanine, AVITGA 
sequence), for this reason, they are also named ‘AVIT proteins’ (Bullock et al., 2004; Kaser 
et al., 2003; Negri et al., 2005); 
- 10 cysteine residues with identical spacing that define a five disulphide bridges, motif called 
a colipase fold, that confer to the molecule a compact three-dimensional conformation and 
high protection from enzymatic degradation (Kaser et al., 2003);  
- A tryptophan (W) residue in position 24, very important for receptor binding.  
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Fig 9. Amino acid sequences of human and mouse PRO Ks and their homologues from frog (Bv8) and snake 
(MIT). AVITGA - dark blue; cysteine (C) - red; tryptophan (W) - light blue. 
 
The amount of data obtained in these first 20 years of research has allowed to classify prokineticins 
as chemokines, despite the fact that phylogenetic studies revealed higher similarity with defensins 
(Monnier and Samson, 2008). Indeed, together with chemokines, Prokineticins are small (8-10 KDa), 
highly basic, secreted peptides which bind sulphate proteoglycans; they contain a high number of 
cysteine residues and are potent chemoattractant (Monnier and Samson, 2008). In addition to the 
initial description of prokineticins as molecules able to induce smooth muscle contractility in the 
gastrointestinal tract, a number of studies have examined other functions of these proteins in 
mammals, such as angiogenesis, neurogenesis, circadian rhythm metabolism, haematopoiesis, 
immune response, reproduction, pain perception (Fig 10). Moreover, the disruption of prokineticin 
system has been implicated in several pathological conditions, including cancer (Shojaei et al., 2007), 
immunological response (Monnier and Samson, 2008), mood disorder (anxiety/depression) (Kishi et 
al., 2009; Li et al., 2009), cardiomyopathy (Attramadal, 2009) and persistent pain (Negri et al., 2009). 
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Fig 10. Prokineticin system is involved in several biological functions. 
 
The prokineticin system plays a key role in coordinating injury-associated nociceptive events because 
it can regulate inflammatory responses and can simultaneously act on different elements of nervous 
system, both at central and at peripheral level (Fig. 11). The activation of prokineticins’ receptors can 
elicit nociception, contributing to nociceptor sensitivity to different stimuli. The first discovery of the 
hyperalgesic effect of the prokineticins came from the observation that systemic injection of the 
amphibian Bv8 in rats induces a characteristic biphasic hyperalgesia to tactile and thermal stimuli 
(Negri et al., 2002). The initial phase of hyperalgesia is caused by a local action on nociceptors, the 
secondary phase, instead, is attributable to a central action (De Felice et al., 2012; Negri et al., 2006) 
indicating differences in the contribution of the prokineticin system at central vs. peripheral sites. 
Prokineticins and their receptors are expressed in regions of the nervous system associated with pain 
(Negri and Lattanzi, 2012). In peripheral nervous system, it has been shown that in DRGs 
prokineticins’ receptors are expressed together with the transient receptor potential vanilloid 1 
(TRPV1) and with the transient receptor potential ankyrin 1 (TRPA1). These co-localizations provide 
the anatomical basis for a cooperative interaction in nociceptor sensitization through activation of 
PKCε (Negri et al., 2006; Vellani et al., 2006). In rat primary sensory neurons PROK2 also enhances 
proton-gate current, suppresses GABA-activated current and sensitizes P2X receptors, via PKC 
signal pathway (Qiu et al., 2012; Ren et al., 2015; Xiong et al., 2010). Evidence that the prokineticin 
system is directly involved in setting the pain threshold comes from studies in mice lacking specific 
prokineticins’ genes: PKR1, PKR2 and PROK2 knock out animals display higher thermal, 
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mechanical and tactile pain threshold compared to wild type mice (Hu et al., 2006; Negri and Lattanzi, 
2012; Negri et al., 2006). At central level in the spinal cord, the highest density of prokineticins’ 
receptors has been found within the dorsal horns indicating that these receptors are involved in central 
transmission of the nociceptive signal (Negri and Lattanzi, 2012). Moreover, prokineticins’ receptors 
are present on astrocytes also containing PROK2 (Guida et al., 2015; Lattanzi et al., 2015; Maftei et 
al., 2014). The prokineticn system also intervenes in modulating central pain mechanism. Intra 
periacqueductal gray (PAG) injection of amphibian protein Bv8 exerts a pro-nociceptive action by 
increasing the intrinsic GABA-ergic tone that, in turn, is responsible for the inhibition of PAG anti-
nociceptive output neurons impinging on rostral ventromedial medulla neurons (de Novellis et al., 
2007; Negri and Lattanzi, 2012). Co-injection with the partial agonist A-24 abolished this central 
effect of Bv8. Peripheral administration of A-24, besides antagonizing the Bv8-induced hyperalgesia, 
increased the opioid content in hypothalamus and midbrain of mice (Lattanzi et al., 2012). 
Lymphoid organs, circulating leukocytes and haematopoietic cells, synoviocytes and dendritic cells 
constitutively express moderate levels of PROK2. Inflammatory stimuli activate the release, from 
fibroblast and endothelial cells, of granulocyte colony-stimulating factor (G-CSF), a major inducer 
of PROK2 which is overexpressed in inflamed tissues and in animal and human neoplastic tissue, 
predominantly in infiltrating neutrophils from which it may be secreted. PROK2, in turn, regulates 
angiogenesis and vessel permeability, activates macrophages and modulates immune responses 
through prokineticins’ receptors expressed on capillary endothelial cells and on leucocytes (Dorsch 
et al., 2005; Franchi et al., 2008; LeCouter et al., 2003b; Martucci et al., 2006; Qu et al., 2012; Shojaei 
et al., 2009). In an animal model of inflammation produced by Complete Freund’s Adjuvant (CFA) 
injection into the paw of rats or mice, PROK2 mRNA (which is quite undetectable in healthy paws) 
dramatically increases in the skin, associated with infiltrating cells (granulocytes and macrophages) 
and temporally correlates with pain and other traits of inflammation as oedema. 24h after the 
injection, PROK2 is significantly increased also in the DRGs ipsilateral to the paw injected with CFA 
(Giannini et al., 2009; Negri and Lattanzi, 2011). Granulocyte released PROK2 modulates acute 
inflammatory pain directly acting on nociceptors and, in turn, exerts chemotactic activities, induces 
a proinflammatory macrophage phenotype and skews the Th1/Th2 balance to Th1 (Franchi et al., 
2008; Martucci et al., 2006). Hence, besides the direct activation of the nociceptors by PROK2, other 
cytokines/chemokines, induced by PROK2, contribute to keep pain in chronic inflammation. There 
are now various reports of prokineticin system dysregulation in inflammatory diseases, for example 
in gut inflammation (Watson et al., 2012), in testis inflammation (Chen et al., 2016), in a mouse 
model of multiple sclerosis, the autoimmune encephalomyelitis (Abou-Hamdan et al., 2015), in a 
mouse model of the human rheumatoid arthritis, Type II collagen induced arthritis (Ito et al., 2016) 
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(Lattanzi and Cuzzocrea, in preparation). In these mice PROK2 gene expression was significantly 
elevated in the joints and correlated with the severity of the arthritis. Repeated treatment with 
prokineticins’ receptors antagonists before the onset of arthritis resulted in significantly lower arthritis 
scores, histological damage and pain, getting along with reduced expression of PROK2 in the synovia. 
 
 
Fig 11. PROK2 induces inflammation and peripheral sensitization. Bone marrow and circulating leukocytes 
constitutively express moderate levels of PROK2. Inflammatory stimuli activate the release, from fibroblast and 
endothelial cells, of G-CSF which, through STAT3 activation, contributes to the recruitment of granulocytes and 
induces PROK2 overexpression in neutrophils infiltrating the inflamed tissues. The released PROK2 regulates 
angiogenesis and vessel permeability, activates macrophages and modulates immune responses acting on PKRs 
expressed by capillary endothelial cells and leucocytes. Moreover, by activating PKR1 and PKR2 on primary 
afferent neurons, PROK2 modulates pain perception; and by activating the PKRs on nociceptor neurons PROK2 
induces Ca2+ mobilization, PKCε translocation, modulation of transducers as TRPV1, TRPA1, ASIC channels, 
P2X channels and reduction of GABAa efficiency [source (Negri and Maftei, 2018)]. 
 
1.3.2 Role of prokineticins in neuropathic pain 
Peripheral nerve injury (CCI or SNI) induces the overexpression of PROK2 and its receptor, PKR2, 
in the sciatic nerve, in lumbar DRGs and in lumbar portion of the spinal cord (Lattanzi et al., 2015; 
Maftei et al., 2014). Analysing mRNA expression, our group has found out that PROK2 and PKR2 
transcripts up-regulation starts 3 days after injury in the sciatic nerve and then it moves towards the 
central nervous system, becoming significant in the spinal cord after 10 days. PROK2 protein, 
normally absent in healthy sciatic nerve, becomes detectable following injury in some axons and it is 
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mainly associated with activated Schwann cells and infiltrating macrophages. Immunofluorescence 
staining of sciatic nerve proximal to the lesion show a dramatic increase also of PKR2 signal. The 
release of PROK2 in the nerve contributes to neuroinflammation (Lattanzi et al., 2015). 6 days after 
injury, both mRNA and protein levels of PROK2 are significantly increased also in the DRG neurons 
and satellite cells and in activated astrocytes within the spinal cord, but not in microglia. In DRGs 
PKR2 immunoreactivity, staining the whole cell body, was evident in many neurons one week after 
surgery. Moreover, at spinal cord level, the increased immunoreactivity of PROK2 associated with 
synaptophysin (a presynaptic marker) indicates that PROK2 may be transported to the central endings 
of nociceptor and then released. Eventually, PROK2 released in the spinal cord activates PKR2 which 
is constitutively localized on the projection neurons and it is up-regulated after nerve injury (Maftei 
et al., 2014). This contributes to spinal glia activation and to the aberrant excitability of the dorsal 
horn which generates allodynia and hyperalgesia, prominent symptoms of neuropathic pain. It is to 
point out that nerve injury induces overexpression also of the receptor PKR1, but only in the sciatic 
nerve, reaching a maximal expression 10 days post-surgery. 
Selective antagonists are extremely useful tool to better characterize the impact of modulations of a   
specific system. Balboni and colleagues have synthesized and developed several nonpeptidic 
prokineticin antagonists (Balboni et al., 2008; Lattanzi et al., 2014), among which the lead compound 
is PC1. This triazine compound mimics the structural features required for prokineticins’ receptor 
binding and experiments conducted by our group demonstrate that PC1 acts as a preferentially PKR1 
ligand. Treatment with prokineticin antagonists is highly efficacious in controlling neuropathic pain. 
A single acute subcutaneous or intraperitoneal injection of PC1 rapidly reduced established pain 
suggesting a direct action on PKRs expressed by nociceptors, whose blockade decreases spinal 
neurons sensitization (Guida et al., 2015) and the transmission of painful stimuli. Therapeutic 
treatment with PC1 (s.c., 1 week) alleviated established thermal hyperalgesia and allodynia, reduced 
the injury-induced overexpression of PROK2, significantly blunted nerve injury-induced microgliosis 
and astrocyte activation in the spinal cord and restored the physiological levels of proinflammatory 
and anti-inflammatory cytokines in periphery and in spinal cord (Maftei et al., 2014). Chronic 
administration of PC1, starting from the day of injury, blocks the onset of mechano-allodynia and 
thermal hyperalgesia and delays the reappearance of painful symptoms 2-3 days after treatment 
suspension, suggesting that blocking PROK2 signalling could induce long lasting changes in neuronal 
circuits and/or in neuroinflammatory phenomena involved (Guida et al., 2015). PC1 treatment also 
normalizes the nerve injury increased permeability of the blood-spinal cord barrier (BSCB) (Guida 
et al., 2015; Maftei et al., 2014) demonstrating the possible involvement of the prokineticin system 
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in the regulation of the neuroinflammatory phenomena leading the infiltration of the peripheral 
immune cells into the spinal cord. 
1.3.3. Prokineticin receptors: structure, distribution and signalling pathways 
Prokineticins exert their biological functions through the activation of two closely related G-protein 
coupled Receptors (GPCRs): Prokineticin Receptor 1 (PKR1) and Prokineticin Receptor 2 (PKR2) 
(Lin et al., 2002a; Masuda et al., 2002; Soga et al., 2002). Although human and mouse genes encoding 
for prokineticin receptors are on two different chromosomes (human: PKR1 gene: 2p13.3; PKR2 
gene: 20p13; mouse: chromosome 6 and 2 respectively), the sequences of both receptors are 
remarkably conserved, displaying more than 85% identity and both of them are about 80% identical 
to the previously described mouse orphan receptor GPR73 (Parker et al., 2000). Most sequence 
variation is concentrated in the extracellular N terminal region - which contains a nine-residue insert 
in PKR1 compared with PKR2 - as well as in the second intracellular loop and in the C terminal tail 
(Levit et al., 2011) (Fig 12). Western blot analysis performed on human neutrophils has shown that 
PKR2 is able to form homodimers and, following heterologous expression of PKR2 in 
Saccharomyces cerevisiae, it has been demonstrated that its dimerization is due to a hydrophobic 
interaction between transmembrane domains. A PKR1-PKR2 heterodimer has also been observed 
(Marsango et al., 2011; Sposini et al., 2015). 
 
 
Fig 12. Snake plot of human PKR1. The secondary structure is according to PKR1 protein annotation in the 
UniProtKB database (entry Q8TCW9). Positions in the PKR1 sequence differing from PKR2 (entry Q8NFJ6) are 
shaded black. Conserved positions between the two subtypes are shaded white. A nine-residue PKR1-unique insert 
in the N terminus is shaded gray with dashed lines. The seven transmembrane domains are denoted by roman 
numerals. Extracellular and intracellular sides of the membrane are labeled, as well as the N terminus (NH2) and C 
terminus (COOH) ends of the protein (Levit et al., 2011). 
33 
 
Several studies show that both prokineticin receptors are distributed throughout the organism: PKR1 
is mainly expressed in peripheral tissues, including endocrine glands and organs of the reproductive 
system, spleen, gastrointestinal tract, lungs, heart and immune cells (such as neutrophils and 
macrophages) whereas, in the central nervous system (CNS) PKR2 is more abundantly expressed and 
PKR1 is present only in discrete brain areas (Cheng et al., 2006; Lin et al., 2002a; Negri et al., 2007; 
Soga et al., 2002). In particular, PKR2 has been found expressed in the paraventricular nucleus, 
arcuate nucleus, dorsomedial hypothalamus and subfornical organ which are the brain areas that 
control ingestive behaviour and the sense of thirst (Gross et al., 1985; Hillebrand et al., 2002; Kalra 
et al., 1999; Negri et al., 2004). Relevant is also the presence of PKR2 in the suprachiasmatic nucleus 
where is implicated in the regulation of circadian rhythm (Cheng et al., 2002; Negri et al., 2004) and 
in several brain areas involved in emotions and mood regulation such as amygdala and hippocampus 
(Cheng et al., 2006).  
Computational (Levit et al., 2011) and genetic (Monnier et al., 2009) analysis indicated the binding 
sites for the endogenous ligands on the extracellular surface of the receptors in correspondence of the 
second extracellular loop and those for the small non-peptide PKRs antagonists and agonists, recently 
identified (Balboni et al., 2008; Gasser et al., 2015), in a pocket located in the upper part of the TM 
bundles among TMs 3, 4, 5, 6 and 7. Computational analysis suggests an identical TM bundle binding 
site for PKR1 and PKR2 so that small-molecules are not likely to easily differentiate between the two 
receptor’s subtypes (Lattanzi et al., 2014; Levit et al., 2011). However, it looks like that agonists and 
antagonists interact with different residues resulting in a totally different area of this pocket. It has 
been also demonstrated that, following stimulation with selective agonists, PKRs undergo rapid 
internalization (Gasser et al., 2015). Except for MIT-1, a clearly PKR2-preferring ligand, and PK2β 
which displays a clear selectivity for PKR1 (Chen et al., 2005), all the other natural prokineticins bind 
and activate both receptors in nanomolar range, with PROK2 showing a moderately higher affinity 
than PROK1 for both receptors (Lin et al., 2002a; Soga et al., 2002). The nonmammalian 
prokineticins (MIT-1 and Bv8) display considerably higher affinity with at least one order of 
magnitude higher compared with human prokineticins. Bv8, that displays similar affinity for both 
receptors, behaves as mammalian PROK2 and is a good pharmacological tool to evaluate the 
prokineticin activities (Negri et al., 2007). 
Several studies show that PKR1 and PKR2 are associated with Gαq, Gαi/o and Gαs proteins. As a 
consequence of this redundancy, prokineticins’ signalling depends on tissue-specific expression of 
ligands, receptors and associated G proteins. As a result, a huge variety of physiological functions in 
response to the same ligand stimulation is possible (Fig 13). In PKRs transfected neuronal and 
specific endothelial cell lines, the activation of PKRs stimulates intracellular calcium mobilization 
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through Gαq coupling. Gαq activates Phospholipase C-β (PLC-β) with the subsequent formation of 
inositol 1,4,5-trisphosphate (IP3) (Lin et al., 2002a). The increase of intracellular calcium leads to the 
activation of calcineurin which subsequently dephosphorylates cytoplasmatic nuclear factor of 
activated T cells (NFAT). This allows NFAT to migrate to the nucleus and bind to specific promoters 
inducing genes transcription (Cook et al., 2010). Lin and colleagues have demonstrated in bovine 
adrenal cortex-derived endothelial (ACE) cells that activation of PKRs induce the phosphorylation 
of p44/42 mitogen-activated protein kinase (MAPK/ERK) pathway and that this mechanism is 
pertussis toxin–sensitive, proving that PKRs may also couple to Gαi/o protein. (Lin et al., 2002b; 
Mangmool and Kurose, 2011). All these data are consistent with the effects of prokineticins on 
smooth muscle contraction and angiogenesis. It has been demonstrated in nociceptors of dorsal root 
ganglia (DRG) that prokineticin receptors’ stimulation increases intracellular concentration of Ca2+ 
by activation of the TRPV1 channels in a dose-dependent manner. In particular, prokineticins’ 
binding to their receptors causes the translocation of protein kinase Cε (PKCε) to the neuronal 
membrane, inducing an enhancement of inward Ca2+ current carried by TRPV1 (Vellani et al., 2006). 
This cross-talk between TRPV1 and PKRs signalling is crucial for nociception (Hu et al., 2006). 
Enteric neural crest cells (NCC) are multipotent progenitors which give rise to neurons and glia of 
the enteric nervous system (ENS) during fetal development. Glial cell line-derived neurotrophic 
factor (GDNF)/RET receptor tyrosine kinase (Ret) signalling is indispensable for their survival, 
migration and differentiation. It has been reported that PKR1 is consistently up-regulated by GDNF 
in enteric NCCs (Ngan et al., 2008; Ruiz-Ferrer et al., 2011) proving that PKRs signalling is also 
important to maintain proliferation and differentiation of enteric NCCs. It has been measured cAMP 
accumulation in in human embryonic kidney cells 293 (HEK293) transiently expressing PKR1 or 
PKR2. The results indicate that prokineticins stimulate cAMP accumulation in PKR-expressing cells 
specifically. HEK293 cells without PKRs expression did not respond to prokineticins stimulation. 
The ligand-stimulated cAMP accumulation is significantly increased if the Gs protein is coexpressed 
with PKRs (Chen et al., 2005). Analysing germline PKR2 variants associated with central 
hypogonadism, it was possible to demonstrate that the two different PKR2-dependent pathways, 
inositol phosphate-Ca2+ (Gq coupling) and cAMP (Gs coupling) can undergo separate modulation 
resulting in patients with alterations of distinct intracellular signalling pathways (Libri et al., 2014).  
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Fig 13. Prokineticin Signalling. PROK1 and PROK2 bind two G-protein coupled receptors (PKR1 and PKR2) 
which are coupling to Gαi, Gαs, Gαq to activate MAPK/Akt, cAMP accumulation and calcium mobilization, 
respectively [Figure adapted from (Ngan et al., 2008)]. 
 
 
1.3.3.1 TM4-7: Identification and characterization of Prokineticin Receptor 2 (PKR2) 
splicing variant 
Alternative splicing of precursor messenger RNA (mRNA) is an essential mechanism to increase the 
complexity of gene expression. Gilbert (Gilbert, 1978) first proposed the concept of alternative 
splicing in 1978, which is currently the mechanism that accounts for the discrepancy between the 
number of protein-coding genes (~25,000) in humans and the >90,000 different proteins that are 
actually generated (1998; 2004). 
Constitutive splicing is the process of intron removal and exon ligation of the majority of the exons 
in the order in which they appear in a gene. During the process of alternative splicing, instead, 
particular exons of a gene may be included within or excluded from the final, processed mRNA 
produced from that gene. Consequently, the proteins translated from alternatively spliced mRNAs 
will contain differences in their amino acid sequence and, more interestingly, in their biological 
activities (Wang et al., 2015). Alternative splicing has a role in almost every aspect of protein 
function, including binding between proteins and ligands, nucleic acids or membranes, localization 
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and enzymatic properties. Taken together, alternative splicing is a central element in gene expression 
(Kelemen et al., 2013). The recognition by the spliceosome of weaker splicing signals at alternative 
splice sites is highly dependent on a system of trans-acting proteins that bind to cis-acting sites on the 
primary transcript itself and, in turn, on cellular context (Chen and Manley, 2009). 
In rat and mouse, PKR2 gene (as well as PKR1 gene) is composed by three exons and two introns. 
The first exon contains a 5’ untranslated sequence (5’ UTR); the second exon contains a part of the 
5’ UTR sequence and a region encoding for the first three transmembrane domains (TM1, TM2 and 
TM3); the third exon encodes for the last four transmembrane domains (TM4, TM5, TM6 and TM7) 
and for the 3’ UTR sequence. The second intron is located at the TM3 border within the common 
DRY (Asp-Arg-Tyr) sequence (Fig 14). Intriguingly, the conservation of certain exon-intron 
boundaries and the relatively high sequence homology between rat and mouse suggests that these two 
receptors are evolutionarily related.  
 
Fig 14. PKR2 gene and mRNA structure. Schematic representation of PKR2 gene structure and the corresponding 
mature mRNA. Each of the three exons encodes for a specific portion of the final protein. 
 
Several years ago, by computational process (Florea et al., 2005), alternatively spliced mRNA 
transcript in rat and in mouse for PKR2 gene had already been predicted. However, only recently, it 
has been demonstrated for the first time the presence of PKR2 splicing variants in vivo in the nervous 
system (Lattanzi et al., Neuropeptides, submitted). Using designed specific primers, it was possible 
to identify in rat hippocampus an mRNA encoding for a PKR2 splicing variant, which, lacking the 
second exon, gives rise to a protein comprising only four transmembrane elements, denominated 
TM4-7 (Fig 15). Through the expression of this splicing variant in yeast, it was possible to deeply 
characterize it. Since mutations in GPCRs sequence could impair their stability, it has been firstly 
demonstrated by fluorescence confocal microscopy that TM4-7 trafficked normally inside the cell 
and it was found expressed on the plasma membrane like PKR2. Afterwards, using 
immunoprecipitation assay, it has been showed that TM4-7 is able to interact with PKR2 long form 
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generating a receptor heterodimer. This last result is in line with previous data showing that 
interactions between PKR2 protomers involve TM4 and TM5 domains (Sposini et al., 2015). 
TM4-7, both as heterodimer and homodimer, shows different functional characteristics in comparison 
to PKR2 wt dimers: in particular, TM4-7 activation induces Gαq and Gαs, but not Gαi coupling 
(Lattanzi et al., Neuropeptides, submitted).  
Besides the differences in signalling pathways, GPCRs’ alternative splice variants often exhibit 
distinct tissue distribution patterns and drug binding properties compared to the respective wt form. 
Moreover, alternative spliced forms can be expressed only in particular cell conditions (Markovic 
and Challiss, 2009; Oladosu et al., 2015). Lattanzi and colleagues have demonstrated, in a murine 
model of Alzheimer’s disease, that TM4-7 transcript was found overexpressed in the hippocampus 
of rats following intracerebroventricular administration of Aβ1-42 (Lattanzi et al., Neuropeptides, 
submitted). Interestingly, in the same animals, the increase of PKR2 wt form was minimal compared 
to the control group, suggesting that the alternative spliced form could be specifically expressed only 
in inflammatory or pathological conditions. Further studies need to be performed to investigate the 
role of TM4-7 in distinct inflammatory/neurodegenerative diseases. 
 
 
 
Fig 15. Scheme of alternative splicing of PKR2 gene exons. A) Exon coding sequences are indicated as white 
bars and untranslated sequences are shown as gray bars. B) Total RNA harvested from hippocampus (HP) and 
cortex (CX) was analysed for PKR2 expression by RT-PCR. Positions of standard markers are indicated on the left. 
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2. AIMS OF THE STUDY 
 
Chronic neuropathic pain represents a huge unmet medical need affecting millions of individuals 
worldwide (Pizzo and Clark, 2012; van Hecke et al., 2014). Opioids have been regarded for millennia 
as among the most effective drugs for the treatment of acute and persistent pain. However, chronic 
opioid exposure give rise to a well-known plethora of side effects such as nausea, constipation, 
tolerance and addiction. Further complications have recently emerged which have the potential to 
increase the morbidity of patients who are on long-term opioid therapy. They include hypogonadism, 
osteoporosis, immune suppression, cognitive impairment and hyperalgesia (Raghavan et al., 2011). 
For these reason novel non-narcotic analgesics are needed. 
Animal models are pivotal for understanding the mechanisms of neuropathic pain and the 
development of effective therapy for its optimal management. A battery of neuropathic pain models 
has been developed to simulate the clinical pain conditions with diverse etiologies. The present study 
was conducted using the well characterized chronic constriction injury (CCI) model (Bennett and 
Xie, 1988) in mice.  
In the last decade both adenosine pathway through A3 receptor and prokineticin system have emerged 
as promising therapeutic targets for the management of neuropathic pain. It is essential to improve 
our mechanistic understanding of their role in chronic pain states in order to develop novel, safe non-
narcotic drugs to present in clinical trials. 
Based on these premises, my PhD work was focused mainly on two projects, aimed at the: 
I) Investigation of A3AR agonists’ mechanism of action in alleviating neuropathic pain  
It has been recently reported that dysregulation of adenosine signalling at the A3 adenosine receptor 
(A3AR) subtype contributes to the development of neuropathic pain states. Accordingly, 
supplementing A3AR signalling with exogenous application of highly selective A3AR agonists block 
and reverse neuropathic pain (Chen et al., 2012; Little et al., 2015; Tosh et al., 2015a; Tosh et al., 
2014). These data identified the A3AR as a target for therapeutic intervention and A3AR agonists as 
a novel approach for chronic pain management (Janes et al., 2016). However, the molecular signalling 
pathways engaged by A3AR agonism remain elusive.  
T cells are essential components of adaptive immunity involved in pain pathology and they actively 
contribute to homeostasis and repair in the nervous system (Laumet et al., 2018). In response to nerve 
injury, T cells infiltrate the sciatic nerve, the dorsal root ganglion (DRG) and the spinal cord (Hu and 
McLachlan, 2002; Lees et al., 2015). Different subsets of T cells are responsible for the production 
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and the release of pro- or anti-inflammatory cytokines and the balance between them determines the 
outcome of the inflammatory response (Neurath, 2014). In particular, CD4+ T cells are known to be 
a prominent source of IL-10 which exerts its action on sensory neurons to reduce pain (Walsh et al., 
2015). Increasing the number of CD4+ T cells in neuropathic pain mice attenuates pain responses 
following CCI surgery, whereas their peripheral depletion resulted in prolonged mechanical pain 
hypersensitivity (Austin et al., 2012). These findings suggest that CD4+ T cells play a role in 
endogenous recovery from neuropathy-induced pain. Thus, this T-cell subset may be specifically 
targeted to alleviate chronic neuropathic pain (Austin et al., 2012; Ji et al., 2016). Previous studies 
have demonstrated that IL-10 is a strong neuroprotective cytokine which promotes neuronal survival 
and has remarkable therapeutic effects in neuropathic pain. A single intrathecal administration of IL-
10 rapidly reverse mechano-allodynia induced by chronic constriction injury (CCI) improving 
animals motor functions for few hours (Lee et al., 2013; Shen et al., 2013; Zhou et al., 2009a), whereas 
viral-mediated delivery of IL-10 after nerve injury has resulted in a more sustained reversal of both 
mechano-allodynia and thermal hyperalgesia for at least 4 weeks (He et al., 2013; Lau et al., 2012). 
Other studies have shown that exogenous administration of IL-10 suppresses allodynia in different 
pain models (Shen et al., 2013) and that inhibition of endogenous IL-10 signalling by intrathecal 
administration of IL-10 antibody prolonged thermal hyperalgesia in a model of transient 
inflammatory pain (Willemen et al., 2014). A3ARs are expressed on the membrane of CD4
+ and 
CD8+ T cells and their expression is increased under pathological settings in correlation with the 
progression of inflammatory response (Ochaion et al., 2009). 
Based on this existing literature, we hypothesized that T cells may be a cellular substrate for A3AR 
agonism. To asses this, wild type, Rag1-/-, A3AR
-/- and IL-10-/- mice were used: animals underwent 
CCI of sciatic nerve and then were reconstituted with an intravenous injection of T cells isolated from 
wild type or different transgenic donors. Onset and development of mechano-allodynia was followed 
up using Von Frey filaments before and after A3AR agonists systemic and intrathecal administration.  
 
II) Investigation of the modulation of prokineticin system following CCI in PKR1 and 
PKR2 knock out mice 
It has been recently reported that prokineticin system is strongly involved in the onset and progression 
of neuropathic pain. In two different animal models (CCI and SNI) treatment with selective 
antagonists of prokineticins’ receptors (PKRs) block and reverse neuropathic pain (Lattanzi et al., 
2015; Maftei et al., 2014). It has been demonstrated that Prokineticin 2 (PROK2), up-regulated in 
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injured sciatic nerve, promotes the recruitment and survival of infiltrating granulocytes and 
macrophages inducing their shift to a pro-inflammatory phenotype by increasing the production of 
IL-1β (Franchi et al., 2008; Martucci et al., 2006) and blocking the release of anti-inflammatory and 
neuroprotective cytokine IL-10 (Lattanzi et al., 2015; Maftei et al., 2014). Moreover, PROK2 
contributes to peripheral sensitization also by directly activating PKRs expressed on sensitive 
neurons: this leads to a reduction of nociceptive threshold thanks to the engaging of TRPV1 and 
TRPA1 signalling. Treatment with selective antagonists of PKRs restores physiological levels of IL-
10 in both sciatic nerve and DRGs (Maftei et al., 2014) and prevents the hyperactivation of astrocytes 
and microglia at spinal cord level, promoting the anti-inflammatory phenotype (Guida et al., 2015). 
All these evidences indicate PKRs as good pharmacological targets for chronic pain management. 
However, several aspects of the modulation and the expression of PKRs in pathological conditions 
remain still unclear.  
Previous studies from our laboratory have demonstrated how mice lacking of prokineticin receptors 
show an impaired nociception and inflammatory pain sensation when compared with WT littermates 
(Negri et al., 2006). Knock out animals are an incredibly useful tool in pharmacological research, so, 
based on this literature, we decided to investigate the behavioural responses induced by peripheral 
nerve ligation in both PKR1-/- and PKR2-/- mice, to better characterize the contribution of each 
receptor in neuropathic pain development.  
For this study, wild type PKR1-/- and PKR2-/- male mice underwent CCI surgery. Onset and 
development of mechano-allodynia and thermal hyperalgesia were followed up using Von Frey 
filaments and Plantar test, respectively. Lumbar region of spinal cord was harvested for 
immunofluorescence assay. 
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3. RESULTS AND DISCUSSION 
 
3.1 A3 adenosine receptor (A3AR) agonists reverse neuropathic pain through a 
CD4+ T cell-dependent IL-10 pathway 
 
3.1.1 Antiallodynic effects of A3AR agonists are completely lost in both Rag1
-/- and IL-
10-/- mice 
Our first hypothesis was that T cells and IL-10 could be important contributors in the mechanism of 
action of A3AR agonists. To assess this, we used mice lacking of mature T and B cells (Rag1
-/-) or 
IL-10 deficient mice (IL-10-/-). After CCI surgery, C57BL/6 wild type (WT), Rag1-/- and IL-10-/- 
mice displayed identical onset and maximal severity of mechano-allodynia in ipsilateral paw. In 
accordance with previous findings (Chen et al., 2012), acute systemic administration of A3AR 
agonists during peak CCI-induced neuropathic pain (day 7-day 8 after surgery) completely reversed 
mechano-allodynia in WT mice, with a fast onset of action (<30 min) and full efficacy within 1 h 
post-dosing, as shown in Fig 1A. However, A3AR agonists completely lost their ability to reverse 
CCI-induced mechano-allodynia when administered i.p. both in Rag1-/- and IL-10-/- mice (Figs. 16A 
and 16C). In order to provide a control experiment, on Day 9 after surgery WT and Rag1-/- mice were 
treated with morphine (3mg/kg s.c.). Anti-allodynic effects of morphine were not affected in Rag1-/- 
mice (Figs. 16E and 16F), showing that Rag1-/- mice are able to respond to analgesics whose 
mechanisms are known not to act via T or B lymphocytes. These findings gave us a first important 
indication: the efficacy of A3AR agonists in reversing neuropathic pain is T cell-mediated and 
involves the release of endogenous IL-10. 
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Fig 16. A3AR agonists lost their ability to reverse CCI-induced neuropathic pain in both Rag1
-/- or IL-10-/- 
mice. CCI-induced mechano-allodynia (manual Von Frey filaments) through Day 8 in Rag1-/- (), IL-10-/- () and 
C57BL/6 wild type () mice. Administration of MRS5980 (1 mg/kg; i.p.) or MRS5698 (1 mg/kg; i.p.) on Day 8 
after surgery reversed mechano-allodynia in ipsilateral paws (A, C) of wild type, but not in Rag1-/- or IL-10-/- mice. 
A3AR agonists’ administration did not affect contralateral PWT (g) (B, D). Anti-allodynic effects of morphine 
(3mg/kg, s.c.) were not affected in Rag1-/- mice (E, F). Data are mean ± SD for n=5-7 mice/group; *p < 0.05 vs D0 
by two-way ANO VA with Dunnett's test; †p < 0.001 vs Rag1 -/- or IL10 -/- by two-way ANOVA with Bonferroni. 
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3.1.2 A3AR agonists’ beneficial effects are mediated by T lymphocytes activation 
To provide evidence that A3AR agonists’ beneficial effects are effectively T-cells mediated, we 
adoptively transferred CD3+ T cells, isolated from spleens and lymph nodes of C57BL/6 WT mice, 
to Rag1-/- mice which underwent CCI surgery. T cells or vehicle were injected intravenously into the 
tail veins of Rag1-/- and WT mice one day before MRS5980 (1 mg/kg i.p.) treatment. Baseline values 
measured on day 8 showed how CD3+ T cell transfer alone did not influence mice pain threshold 
after CCI surgery (Fig 17). Following MRS5980 administration, as expected, Rag1-/- mice that did 
not receive CD3+ T cells were not able to reverse CCI-induced mechano-allodynia (Fig 17A); on the 
contrary, Rag1-/- mice reconstituted with CD3+ T cells gained the ability to respond to MRS5980 at 
rates comparable to WT mice (Fig 17B). With these results we confirmed that A3AR agonists’ 
beneficial effects rely on the modulation of inflammatory process through the involvement of T cells 
and the enhancement of their immune response. 
 
 
Fig 17. Adoptive CD3+ T cells transfer restored A3AR agonists’ beneficial effects in Rag1
-/- mice. Rag1-/- mice 
() are not able to respond to A3AR agonists after CCI surgery (A). But, following CD3+ T cell transfer, they 
gained the ability to respond to MRS5980 and reversed mechano-allodynia in ipsilateral paws at rates comparable 
to WT mice () (B). MRS5980 treatment or CD3+ T cell transfer did not affect contralateral PWT (g) (C, D). Data 
are mean ± SD for n=5-7 mice/group; *p < 0.05 vs D0, †p < 0.001 vs D8 by two-way ANOVA with Dunnett's test. 
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To further explore the key players responsible for A3AR agonists’ beneficial effects, we then focused 
our research on the identification of the T cells’ subset involved in our drugs’ mechanisms of action. 
WT and Rag1-/- mice received either CD4+ T cells, CD8+ T cells or vehicle intravenously on day 7 
after CCI surgery. Acute intraperitoneal administration of MRS5980 on day 8 reversed, also if not 
completely, mechano-allodynia in Rag1-/- mice receiving CD4+ T cells (Fig 18A). In contrast, 
mechano-allodynia persisted in mice that were transferred with only CD8+ T cells (Fig 18C). These 
data showed how CD4+ T cells are the T cell subset mainly involved in A3AR agonists’ action. 
 
 
 
Fig 18. Identification of T cells subset mainly responsible for A3AR agonists’ beneficial effects. (A, C) CD4
+ 
(), CD8+ () T cells or vehicle (), were injected i.v. to Rag1-/- mice one day before MRS5980 i.p. 
administration. Rag1-/- mice receiving CD4+ T cells reversed mechano-allodynia but not at rates comparable to WT 
mice (), whereas Rag1-/- mice reconstituted with CD8+ T cells were not able to respond to MRS5980. MRS5980 
treatment or T cell transfer did not affect contralateral PWT (g) (B, D). Data are mean ± SD for n=5-7 mice/group; 
*p < 0.05 vs D0 by two-way ANOVA with Dunnett's test; †p < 0.001 vs Rag1-/- (vehicle) or Rag1-/- 
(vehicle/CD4+/CD8+) or WT by two-way ANOVA with Turkey comparisons.  
 
45 
 
To investigate if in CCI model A3AR agonists can directly modulate T cells’ activity, we used two 
different approaches. In the first one, A3AR
-/- mice were used as donors of CD4+ T cells. On day 7 
after surgery, Rag1-/- mice received an i.v. injection of vehicle or CD4+ T cells previously isolated 
from A3AR-/- mice, so in this case in recipient mice the receptor is express throughout the body 
except on CD4+ T cells. Acute intraperitoneal administration of MRS5980 on day 8 had no effect on 
ipsilateral paw withdrawal threshold (PWT) of Rag1-/- mice compared to the complete reversal of 
mechano-allodynia observed in WT mice (Fig 19A). This first result clearly proves a direct action of 
the A3AR agonists on A3AR expressed on CD4
+ T cells.  
Through the second approach, we wanted to examine the specificity of MRS5980 action. In this 
experiment, A3AR
-/- mice underwent CCI surgery and 7 days later they received an i.v. injection of 
CD4+ T cells isolated from WT donors. In this case in recipient mice A3AR is expressed only on the 
membrane of CD4+ T cells. Acute intraperitoneal administration of MRS5980 on day 8 totally 
reversed established mechano-allodynia in A3AR-/- mice receiving CD4+ T cells as well as in WT 
mice (Fig 19C). As expected, no effect was observed in the control group. Contralateral PWT did not 
differ from baseline at any time point (Fig 19 B, D). 
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Fig 19. The action of the A3AR agonist MRS5980 is mediated by A3AR expressed on CD4+ T cells. CD4+ T 
cells isolated from A3AR
-/- donors () or vehicle (), were injected i.v. to Rag1-/- mice one day before MRS5980 
i.p. administration. Rag1-/- mice reconstituted with CD4+ T cells were not able to respond to MRS5980 (A). A3AR
-
/- mice received either wild type CD4+ T cells () or vehicle () on day 7 after CCI. The following day, A3AR-/- 
mice reconstituted with CD4+ T cells completely reversed CCI-induced mechano-allodynia after MRS5980 i.p. 
administration (C). MRS5980 treatment or T cell transfer did not affect contralateral PWT (g) (D, B). Data are mean 
± SD for n=5-7 mice/group; *p < 0.05 vs D0 and †p < 0.001 vs D8 by two-way ANOVA with Dunnett's test. 
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3.1.3 Investigation of CD4+ T cells site of action 
To investigate the site of action of A3AR agonists, on day 9 after surgery MRS5980 (3nmol) was 
administered intrathecally (i.t) to both WT and Rag1-/- mice reconstituted with T cells. Similarly to 
results obtained with intraperitoneal administration, Rag1-/- mice reconstituted with CD3+ T cells 
rapidly reversed mechano-allodynia at rates comparable to WT mice. Beneficial effects of MRS5980 
were evident, though slightly attenuated, in Rag1-/- mice reconstituted only with CD4+ T cells subset, 
whereas the degree of reversal observed in mice that received CD8+ T cells was minimal (Fig 20).  
 
 
Fig 20. Investigation of a possible A3AR agonists’ site of action. CD3+ (), CD4+ (), CD8+ () T cells or 
vehicle (), were injected i.v. to Rag1-/- mice two days before MRS5980 (3nmol; i.t.) administration. Rag1-/- mice 
receiving CD3+ T cells reversed CCI-induced mechano-allodynia at rates comparable to WT mice () (A), whereas 
in mice reconstituted with CD4+ or CD8+ T cells MRS5980 beneficial effects were evident, but not complete, or 
minimal respectively (B). MRS5980 treatment or T cell transfer did not affect contralateral PWT (g) (B, D). Data 
are mean ± SD for n=5-7 mice/group; *p < 0.05 vs D0; †p < 0.001 vs D8 by two-way ANOVA with Dunnett's test. 
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These results obtained in Rag1-/- mice suggest that A3AR agonists act on activated T cells which 
infiltrate DRGs and/or spinal cord in response to molecular signals to modulate inflammation. To 
verify this hypothesis, we stained CD4+ T cells in the lumbar sections of spinal cord and in DRGs. 
Immunofluorescence analysis showed CD4+ T cells infiltration in the DRGs of Rag1-/- mice 
reconstituted with CD4+ T cells from WT donors, compared to Rag1-/- received the vehicle (data in 
progress). In particular, our data demonstrated that following CCI, A3AR agonists’ administration 
evokes trafficking of immune cells from circulation into the DRGs and that these neuroimmune 
interactions play a critical role in the therapeutic effects of A3AR agonists in alleviating neuropathic 
pain. 
 
 
 
3.1.4 CD4+ T cells are the source of IL-10 needed for A3AR agonists’ beneficial effects 
Our findings demonstrated that CD4+ T cells are key players in A3AR agonists’ mechanism of action. 
CD4+ T cells are known to be essential for the resolution of inflammatory process through the release 
of IL-10. Since our very first results (Fig 16C) showed that A3AR agonists’ beneficial effects are 
strictly dependent on endogenous release of this interleukin, we decided to investigate the cellular 
source of IL-10. On day 7 after CCI surgery, Rag1-/- mice received i.v. vehicle or CD4+ T cells, either 
from WT or IL-10-/- mice donors. As we already shown, adoptive transfer of CD4+ T cells from WT 
donors completely restored the beneficial effects of A3AR agonists in Rag1-/- mice (Fig 21A). 
However, CD4+ T cells from IL-10-/- mice donors provided no restoration (Fig 21C). This result 
proved that A3AR agonists reverse CCI-induced mechano-allodynia through a CD4
+ T cells-
dependent IL-10 pathway. 
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Fig 21. A3AR agonists reverse CCI-induced mechano-allodynia through a CD4
+ T cells-dependent IL-10 
pathway. Rag1-/- mice were transferred with CD4+ T cells isolated from either WT () (A), or IL10-/- () (C) 
donors. Rag1-/- mice transferred with CD4+ T cells from WT donors reversed mechano-allodynia also if not at rates 
comparable to WT mice (). On the contrary, Rag1-/- mice transferred with CD4+ T cells from IL10-/- donors 
completely lose the ability to respond to A3AR agonist as well as Rag1
-/- mice injected i.v. with vehicle (). Data 
are mean ± SD for n=5-7 mice/group; *p < 0.05 vs D0; †p < 0.001 vs D8 by two-way ANOVA with Dunnett's test.  
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3.1.5 Discussion  
In this study, using a well-characterized model of chronic neuropathic pain resulting from constriction 
of the sciatic nerve in mice (Bennett and Xie, 1988), we have demonstrated for the first time that 
A3AR agonists are able to reverse established mechano-allodynia through a T cell driven pathway.  
A3AR is expressed on the membrane of different immune cells (Borea et al., 2015) and its expression 
resulted increased in pathological conditions, in correlation with the progression of inflammatory 
response (Ochaion et al., 2009), suggesting that its activation could be directly involved in immune 
cells’ activities. Our first results reported how A3AR agonists’ beneficial effects are completely lost 
in mice deficient of mature B and T cells (Rag1-/-). However, following CD3+ T cells adoptive 
transfer, Rag1-/- animals gain the ability to respond to A3AR agonists and completely reverse 
neuropathic pain at rates comparable with wild type mice. We further investigated the different T 
cells’ subtypes involved in this mechanism and we identified the CD4+ T cells as the major 
contributor in the analgesic effects induced by A3AR agonists administration. The balance of specific 
cytokines secreted by CD4+ and CD8+ T cells determines the outcome of the inflammatory response 
after injury (Neurath, 2014). Targeting immune cells to modulate cytokines profile is a winning 
strategy to control the progress of inflammatory process thus preventing its chronicization, which 
represent the main trigger for the establishment of neuropathic pain states. It has been reported that 
CD4+ T cells activity is critical for alleviating neuropathic pain (Austin et al., 2012; Ji et al., 2016). 
Here we confirmed the crucial role of these cells in modulating anti-inflammatory response, 
demonstrating that this T cell subset is the one mainly involved in A3AR agonists’ mechanism of 
action. Interestingly, it has been recently reported that also activated cytotoxic CD8+ T cells have a 
protective role in different models of chronic inflammatory pain (Baddack-Werncke et al., 2017; 
Krukowski et al., 2016). The switch of CD8+ T cells to a cytotoxic phenotype is largely due to CD4+ 
T cells through the release of Interleukin-2 (IL-2) and the involvement of dendritic cells (Boyman 
and Sprent, 2012; Mailliard et al., 2002; Melief, 2013). Therefore, it is possible that CD8+ T cell 
adoptive transfer in Rag1-/- mice was not sufficient to elicit A3AR agonists’ effects because they 
failed their complete activation in absence of CD4+ T cell. However, also if CD8+ T cells could 
partially contribute to the final effects of our drugs, our data clearly showed that CD4+ T cells are the 
driving force in A3AR agonists’ action. 
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MRS5980, the A3AR agonist used in this study, was recently developed and characterized (Fang et 
al., 2015; Tosh et al., 2015a). We have shown how anti-nociceptive effects of this drug are lost in 
A3AR
-/- mice, confirming its high specificity at A3AR. More interestingly, however, was the 
demonstration that, in this model, its beneficial effects in abrogate neuropathic pain are exclusively 
due to its action on a specific subpopulation of T lymphocytes. When systemically administered to 
neuropathic A3AR
-/- mice previously transferred with wild type CD4+ T cells, in fact, the anti-
allodynic effects of MRS5980 were comparable to the results obtained in wild type mice. Together 
with the data obtained in Rag1-/- mice, these results demonstrate that the presence of A3 receptor on 
CD4+ T cells is necessary and sufficient to elicit a complete analgesic response to the drug. 
To corroborate this assumption, we have also reported that in Rag1-/- mice intrathecal injection of 
A3AR agonists did not evoke an analgesic response, demonstrating that cells in DRGs or in the spinal 
cord, such as astrocytes, are not a predominant target for our drug in this model. 
A3AR activation is associated to protective effects throughout the organism, since it enhances 
physiological functions in almost all tissues (Borea et al., 2015). However, prolonged stimulation or 
the usage of high drug doses for a long-term treatment, could lead to the appearance of undesired side 
effects. For this reason, the possibility to obtain a great analgesic effect by intrathecal administration, 
as the one observed with our agonist, can decrease the side effects typically associated with oral or 
parental drug delivery and may allow for better quality of life outcomes in patients with chronic pain. 
In this work we have also shown how, following peripheral nerve injury, CD4+ T cells infiltrate the 
DRGs where are the specific target of A3AR agonists. Many studies have been performed, using 
different neuropathic pain models, to investigate the contribute of lymphocyte infiltration to the 
development and the maintenance of persistent pain, but this phenomenon remains somewhat 
controversial (Gattlen et al., 2016; Walsh et al., 2015). T cell infiltration into spinal cord and DRGs 
has been reported as contributor to mechanical hypersensitivity in several pain models including CCI 
and spinal nerve ligation/transection (Costigan et al., 2009; Grace et al., 2011; Hu and McLachlan, 
2002). These infiltrating lymphocytes were found to be constituted predominantly by CD4+ T cells 
(Cao and DeLeo, 2008) which are known to be the major player in the adaptive immune response 
following injury. In our experiments we have shown that Rag1-/- mice develop the same level of 
hypersensitivity of WT mice after CCI and we found no evidence of the fact that Rag1-/- mice could 
experience a stronger pain sensation following T cells’ injection. So, in our hands, there are no 
evidence for a role of T cells in the modulation of nociception. Thorough analysis, both in vitro and 
in vivo, have demonstrated that the dominant CD4+ T cell subtype involved in this mechanism are the 
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T helper 1 (Th1) cells, which contributes to the establishment of chronic inflammation in a microglia-
independent manner, via a mechanism that could involve multiple Th1 inflammatory cytokines 
release and astrocytic activation (Draleau et al., 2014; Moalem et al., 2004). On the contrary, our 
findings, clearly evidence that A3AR agonists act on a subpopulation of CD4
+ T cell able to produce 
and release IL-10, such as T helper 2 (Th2) or T regulatory (Tregs) cells. The strategy of enhance 
infiltrating T cells activity to alleviate persistent pain has been also reported by Leger and colleagues: 
Glatiramer, a synthetic amino acid polymer that is known to induce the development of Th2 and 
enhance the production of IL-10 (Aharoni et al., 2003), when administered systemically reversed 
neuropathic allodynia and increased IL-10 expressing T cells in neuropathic dorsal horns (Leger et 
al., 2011). 
Further, we have proven that A3AR agonists’ beneficial effects strictly depend on the release of IL-
10, since they are completely lost in IL-10-/- animals, confirming the IL-10 downstream of A3AR 
activation previously reported (Wahlman et al., 2018). In particular, our results demonstrate that 
A3AR agonists are able to reverse CCI-induced neuropathic pain by modifying cytokines’ profile 
released during inflammation process, acting directly on CD4+ T cells and inducing the release of 
IL-10. It has been widely reported that IL-10 suppresses cellular immunity and inhibits the synthesis 
and release of pro-nociceptive mediators such as TNFα, IL1-β, IL-6, IL-8 and IL-12 (Howard and 
O'Garra, 1992; Ledeboer et al., 2002; Moore et al., 2001). More recently, in addition to its anti-
inflammatory effects, it has been demonstrated that IL-10 exerts also direct effects on 
neurons. Expression of IL-10 receptor mRNA and protein has been found in spinal cord neurons in 
vitro where IL-10 activates signalling pathways involved in neuroprotection and growth to overcome 
the neurotoxic effects of glutamate (Zhou et al., 2009b). In vivo studies, in a model of spinal cord 
injury, confirmed that IL-10 promotes neuronal survival and improves motor function (Zhou et al., 
2009a). In neurons, the effects of IL-10 against glutamate-induced excitotoxicity are mediated 
through Jak-Stat3 and PI3K/AKT pathways, both involved in the transcription of survival genes and 
intracellular Ca2+ levels normalization (Sharma et al., 2011; Turovskaya et al., 2012; Zhou et al., 
2009b). In DRG it has been demonstrated that IL-10, acting through IL-10R1 receptor, down-
regulates the over-expression of voltage-gated sodium channels reducing the hyperexcitability of 
DRG neurons induced by nerve injury (Shen et al., 2013). This data could explain the rapid analgesic 
effects that we observed following A3AR agonists administration and, interestingly, they also 
correlate with our previous findings which reported how A3AR activation in CCI animals inhibits 
nociceptive processing by reducing spinal neuronal excitability (Little et al., 2015). 
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In summary, we have demonstrated for the first time that treatment with A3AR agonists following 
peripheral nerve injury has surprising therapeutic results that converge in considerably attenuating 
abnormal nociception. This study suggests A3AR agonists therapy, which has already been proven 
safe in the clinic in other inflammatory diseases (David et al., 2016; Stemmer et al., 2013), may 
provide a novel treatment also for chronic neuropathic pain. 
 
 
Fig 22. Schematic representation of a possible mechanisms underlying A3AR-induced anti-nociception. A3AR 
agonists, acting specifically on the receptor expressed by CD4+ T cells, induce the release of IL-10. The activation 
of IL-10 receptors on glial cells inhibits the release of pro-inflammatory cytokines such as IL-1β, whereas the 
activation of neuronal IL-10 receptors, restores intracellular calcium levels, reducing neuronal excitability 
(Ledeboer et al., 2002; Sharma et al., 2011; Turovskaya et al., 2012). 
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3.2. New insight in the role of prokineticin system in neuropathic pain: TM4-7 
involvement the development of contralateral neuropathy in PKR1-/- mice 
 
3.2.1. CCI-induced neuropathic pain in WT, PKR1-/- and PKR2-/- mice: the discovery of 
contralateral neuropathy 
Previous work from our group, have demonstrated a central role of the prokineticin system in the 
development and maintenance of neuropathic pain. Sciatic nerve ligation induces an overexpression 
of PROK2 which is involved in peripheral inflammation through the recruitment of neutrophils and 
macrophages, and in central sensitization since it contributes to spinal glia activation and aberrant 
excitation of projection neurons in the dorsal horn (Lattanzi et al., 2015; Maftei et al., 2014). PKRs 
expression has been also investigated in neuropathic WT mice: nerve damage induces a strong 
overexpression of PKR2 both in peripheral and central nervous system, whereas PKR1 significantly 
increase only in injured sciatic nerve (Negri and Maftei, 2018).  
Based on these previous observations, we decided to investigate the behavioural responses induced 
by peripheral nerve ligation in both PKR1-/- and PKR2-/- mice, to better characterize the contribution 
of each receptor in neuropathic pain development. Following CCI surgery, thermal hyperalgesia 
(plantar test) and mechano-allodynia (Von Frey filaments) were followed up for more than 3 months. 
WT and PKR2-/- mice displayed identical onset and maximal severity of thermal hyperalgesia and 
mechano-allodynia in ipsilateral paws. PKR1-/- mice, instead, developed a strong hypersensitivity 
only on contralateral paws, showing hyperalgesia and allodynia at rates comparable to the ones 
observed in ipsilateral paws of the other two experimental groups (Fig 23).   
Thermal hyperalgesia was already evident in ipsilateral paws of WT and PKR2-/- and in contralateral 
paws of PKR1-/- mice 3 days after CCI (Fig 23A). By post-CCI day 45-50 all animals showed a 
gradual increase in thermal nociceptive threshold, until the complete recovery 55 days after surgery. 
Interestingly, in PKR2-/- mice recovery was slower and thermal hyperalgesia still persisted, also if 
attenuated, until 70-80 days after CCI. Starting from post-CCI day 10, mechanical nociceptive 
threshold (Fig 23B) decreases of 40%–50% in the ipsilateral compared to contralateral hind paws in 
both WT and PKR2-/- mice, whereas PKR1-/- mice developed allodynia on contralateral hind paws. 
By post-CCI day 45-50, in both WT and PKR2-/- mice allodynia gradually decreased and there was a 
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significant increase of the mechanical threshold, until the complete recovery 70 days after surgery. 
In PKR1-/- mice mechano-allodynia still persisted, also if slightly attenuated, until 100 days after CCI. 
 
 
Fig 23. PKR1-/- mice developed contralateral neuropathy following CCI surgery. Time-course of CCI-induced 
thermal hyperalgesia (A, plantar test) and mechano-allodynia (B, manual Von Frey filaments) in WT, PKR1-/-and 
PKR2-/- mice. Values are referred to measurements on hind paws ipsilateral () and contralateral () to the injury. 
Data are mean ± SD for n=5-7 mice/group; *p < 0.05, **p < 0.01 and ***p < 0.001 vs contralateral paws by two-
way ANOVA with Bonferroni. 
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3.2.2.  Investigation of prokineticin system alterations following CCI-induced 
neuropathic pain  
Considering the results obtained by behavioural tests, we decided to investigate the expression of 
PROK2 and PKR2 in PKR1-/- mice in comparison with WT animals.  
As expected, immunofluorescence analysis (Fig 24A) performed on mice sacrificed 10 days after 
CCI, showed a strong overexpression of PROK2 in both WT and PKR1-/- mice in ipsilateral dorsal 
horn compared to its faint expression in sham animals. 
An interesting data, instead, came out by observing the contralateral dorsal horns. A very low 
expression of PROK2 was detected in WT mice, confirming previous findings (Maftei et al., 2014) 
but, curiously, high levels of PROK2 were present in dorsal horns of PKR1-/- mice (Fig 24B). 
 
Fig 24. PKR1-/- mice, following CCI surgery, shows high levels of PROK2 in both ipsilateral and contralateral 
dorsal horn. A) PROK2 positive profiles (green) and GFAP (astrocytes marker) positive profile (red) in WT and 
PKR1-/- mice. B) Quantification of PROK2 in the spinal cord. Sciatic nerve ligation induced a substantial increase 
of PROK2 signal 10 days after surgery in ipsilateral dorsal horn of both WT and PKR1-/- mice. However, elevate 
expression of PROK2 was also detected in contralateral dorsal horn of PKR1-/- mice, whereas, as expected, almost 
no signal was detected in WT mice. Cell nuclei were counterstained with DAPI (blue). Scale bar: 50μm.  
***p < 0.001 vs WT sham; °°° p < 0.001 and °°p < 0.01 vs KO sham by one-way ANOVA with Tukey’s. 
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PKR2 expression has been also investigated. As showed in figure 25, immunofluorescence staining 
revealed a faint PKR2 immunoreactivity in both WT and PKR1-/- sham mice. 10 days after CCI, 
PKR2 immunofluorescence was strongly increased in the ipsilateral dorsal horn of both WT and 
PKR1-/- mice, mainly associated with neuronal cells (NeuN-positive cells, in red). No differences 
were observed in the expression of PKR2 between WT and PKR1-/- neuropathic mice in contralateral 
dorsal horns: in both experimental groups the receptor result not modulated in this area after the 
surgery. 
 
 
 
Fig 25. Following CCI surgery, WT and PKR1-/- mice show the same expression pattern of PKR2 in the spinal 
cord. A) PKR2 positive profiles (green) and NeuN (neuronal marker) positive profile (red) in WT and PKR1-/- mice. 
B) Quantification of PKR2 in the spinal cord. Sciatic nerve ligation induced a substantial increase of PKR2 signal 
10 days after surgery in ipsilateral dorsal horn of both WT and PKR1-/- mice compared to sham animals. Very low 
expression of PKR2, instead, was detected in contralateral dorsal horn of all mice. Cell nuclei were counterstained 
with DAPI (blue). Scale bar: 50μm. *p < 0.05 vs WT sham; °p < 0.05 vs KO sham by one-way ANOVA with 
Tukey’s. 
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3.2.4. Discussion 
In this study, using a well-characterized model of chronic neuropathic pain resulting from constriction 
of the sciatic nerve in mice (Bennett and Xie, 1988) we investigated for the first time the modulation 
of PKR1 and PKR2. 
Prokineticin system has been reported to be involved in a great number of physiological functions 
and thus its alterations underlie pathological mechanisms of several diseases. In particular, in the last 
few years, important results have been achieved in the comprehension on how this system can 
contribute to the development and maintenance of neuropathic pain states (Lattanzi et al., 2015; 
Maftei et al., 2014). Previous studies from our laboratory have demonstrated how mice lacking of 
prokineticin receptors show an impaired nociception and inflammatory pain sensation when 
compared with WT littermates (Negri et al., 2006). Knock out animals are an incredibly useful tool 
in pharmacological research, so, based on this literature, we decided to investigate the behavioural 
responses induced by peripheral nerve ligation in both PKR1-/- and PKR2-/- mice, to better 
characterize the contribution of each receptor in neuropathic pain development.  
What came out from our very first experiment was unexpected and extremely interesting: almost 
immediately after CCI surgery, PKR1-/- mice developed a marked hypersensitivity to the contralateral 
paw, whereas both mechano-allodynia and thermal hyperalgesia threshold remain at baseline values 
in ipsilateral paw. PKR2-/- mice, instead, showed a “classical” development of neuropathic pain on 
ipsilateral side, at rates comparable with WT mice.  
Modulation of prokineticin system in neuropathic pain conditions has been widely investigated in 
previous works from our lab (Lattanzi et al., 2015; Maftei et al., 2014; Negri and Maftei, 2018). 
However, no biochemical characterization of prokineticin system had been performed before on 
knock-out animals. Considering the puzzling behavioural results obtained, we decided to deeply 
investigate prokineticin system modulation in PKR1-/- mice. As expected, immunofluorescence 
analysis on lumbar spinal cord samples showed an overexpression of PROK2 in ipsilateral dorsal 
horn of WT mice. In PKR1-/- mice, instead, PROK2 resulted overexpressed both in ipsilateral and in 
contralateral portion of the spinal cord. This result, could partially explain what we observed during 
behavioural tests: whilst the fact that PROK2 is overexpressed on contralateral side could explain the 
contralateral neuropathy we measured, the fact that it is still elevated in ipsilateral side arises the 
question on why we can’t register pain on ipsilateral side. Trying to find the answer, we also 
investigated PKR2 expression in the spinal cord. As previously reported (Maftei et al., 2014) the 
receptor results overexpressed following nerve ligation in ipsilateral dorsal horn of WT mice and 
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here, we confirmed this data. Once again, however, results in PKR1-/- mice surprised us: they showed 
the exact same pattern of expression of PKR2 observed in WT mice: high in ipsilateral side, but low 
in contralateral side.  
Recently a spliced form of PKR2, named TM4-7, has been identified and characterized (Lattanzi et 
al., Neuropeptides, submitted). This alternative spliced form results overexpressed in correlation with 
inflammatory response. It could be possible that PROK2 overexpressed in contralateral side, could 
act on this spliced form instead of on wt form, and induce hypersensitivity on the contralateral side. 
No antibodies are available so far to target this truncated receptor. The one we have at the moment, 
binds the N-terminal region of PKR2, so it cannot recognize TM4-7 since, as its name indicates, it is 
lacking of the first 3 transmembrane regions, including N-terminal portion.  
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4. CONCLUSIONS 
 
The data presented in this work throw new light on how we could intervene on such a huge medical 
need with major socioeconomic consequences as is the treatment of neuropathic pain. 
A first approach is the blockade of pathways that contribute to neuroinflammation. Its overall 
accepted that activation of prokineticin system plays a critical role in development and maintenance 
of neuropathic pain. However, the latest data obtained on PKRs modulation increase our mechanistic 
understanding of the role of this system in chronic pain states. PKRs confirm its role as promising 
pharmacological target for the development of novel non-narcotic drugs to alleviate chronic pain. 
The second approach is to empower anti-inflammatory and neuroprotective mechanisms: endogenous 
adenosine signals via A3AR inhibit chronic neuropathic pain and A3AR agonists have already 
advanced in clinical trials for non-pain indications showing a good safety profile. The findings 
presented in this work deeply investigate A3AR agonists mechanism of action providing foundational 
and mechanistic rationale to support the clinical evaluation of these drugs also in neuropathic pain 
patients. 
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5. MATERIALS AND METHODS 
 
5.1 Animals 
Rag1 knock out (B6.129S7-Rag1tm1Mom/J), IL-10 knock out (B6.129P2-IL-10tm1Cgn/J) A3AR 
knock out and wild-type (C57BL/6) male mice from The Jackson Laboratory (Bar Harbor, ME, USA) 
were used for the experiments on A3 Adenosine Receptor (A3AR) agonists. Experiments were 
performed in accordance with International Association for the Study of Pain, U.S. National Institutes 
of Health guidelines on laboratory animal welfare, and St. Louis University Institutional Animal Care 
and Use Committee recommendations. 
C57BL/6J wild-type and PKR1 knock out male mice from Lexicon Genetics (The Woodlands, TX, 
USA) were used for the experiments on Prokineticin system. Each protocol was approved by the 
Animal Care and Use Committee of the Italian Ministry of Health according to European Commission 
directives. 
All animals weighed approximately 20-30 g at the moment of experiments and were housed 5/cage 
in a controlled environment (12-h light-dark cycles, 21 ± 2°C, 50-60% humidity) with food and water 
available ad libitum. All efforts were made to minimize the number of animals used and their 
suffering. Experimenters were blinded to treatment conditions in all experiments. 
 
5.2 Test Compounds 
In this study, the highly selective A3AR agonists, MRS5698, 2-(3,4-difluorophenylethynyl)-N6-(3-
chlorobenzyl)-(N)-methanocarba-adenosine-5′-methyluronamide (Tosh et al., 2012) and MRS5980, 
(1S,2R,3S,4R,5S)-4-(2-((5-chlorothiophen-2-yl)ethynyl)-6-(methylamino)-9H-purin-9-yl)-2,3-
dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (Tosh et al., 2014) were used. Morphine 
was a kind gift from Mallinckrodt (St. Louis, MO, USA). 
 
 
5.3 Procedures 
 
5.3.1 CCI model of neuropathic pain 
Chronic constriction injury to the sciatic nerve of the right hind leg in mice was performed under 
general anaesthesia using the well-characterized Bennett model (Bennett and Xie, 1988). Briefly, 
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mice were anesthetized either with 3% isoflurane/100% O2 inhalation and maintained on 2% 
isoflurane/100% O2 for the duration of surgery or with an intraperitoneal (i.p.) injection of a mixture 
of ketamine (60 mg/kg, Imalgene, Merial, Toulouse, France) and xylazine (10 mg/kg, Sigma-Aldrich, 
Saint Louis, MO, USA). The right thigh was shaved and a small incision (1–1.5 cm in length) was 
made in the middle of the lateral aspect of the right thigh to expose the sciatic nerve. The nerve was 
loosely ligated around the entire diameter at 3 distinct sites (spaced 1 mm apart) using silk sutures 
(6.0). The surgical site was then closed either a skin clip or with a silk suture (4.0). Mice were then 
allowed to recover in a heated cage until all reflexes were normalized. The injured and uninjured hind 
paws were named as ipsilateral and contralateral hind paw, respectively. 
 
5.3.2 T cell isolation and adoptive transfer 
Single-cell suspensions were obtained from spleens and lymph nodes of C57BL/6 WT, IL-10 knock 
out and A3AR knock out mice by passing organs through 70µm strainers, after which cells were 
washed with PBS plus 0.1% bovine serum albumin. T-cell population was purified by negative 
selection. Briefly, T-cells were incubated with biotinylated antibodies against CD11b, CD11c, 
CD49b, B220, TER-119, CD4 and CD8a, all purchased from BioLegend, and they were negatively 
selected by autoMACS sorting. After MACS purification, T-cells were washed, counted and 
resuspended in PBS for intravenous injections (2 x 106/mouse). On Day 7 after CCI surgery, T cells 
or PBS were injected intravenously (i.v.) into the tail vein in a volume of 200µl. An aliquot of the 
sorted population was assessed for the purity check analysis: cells were labeled with anti-CD3-FITC 
or with anti-CD4-PeCy7 and the purity was determined by FlowCytometry. 
 
 
5.3.3 Drugs injection 
The highly selective A3AR agonists, MRS5698 (1 mg/kg) and MRS5980 (1 mg/kg), were 
administered intraperitoneally (i.p.) on Day 8 after CCI surgery. Both compounds were dissolved in 
a solution of 10% of Dymethyl Sulfoxide (DMSO) in sterile saline. MRS5980 (3nmol/mouse) was 
administered also intrathecally (i.th.) to investigate its site of action. The drug also in this case was 
dissolved in a solution of 10% of DMSO in sterile saline. Morphine (3 mg/kg) was dissolved in sterile 
saline and administered i.p. on Day 9 after CCI surgery. 
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5.4 Behavioural Testing 
 
5.4.1 Measurement of thermal hyperalgesia 
For testing heat sensitivity, animals were put in plastic boxes and allowed 20-30 min for habituation 
before examination. Heat sensitivity was tested by radiant heat using Hargreaves apparatus (Ugo 
Basile, Italy) and expressed as paw withdrawal latency (PWL). The infrared emitter/detector was put 
directly underneath the plantar aspect of hindpaws. The radiant heat intensity was adjusted so that 
basal PWL is between 10 and 12 s with a cut-off of 20 s to prevent tissue damage. 
 
5.4.2 Measurement of mechanical allodynia 
Mechano-allodynia was measured after first acclimating the animals to elevated cages with a wire 
mesh floor for 15-20 min. The plantar aspect of hindpaws was probed 3 times with calibrated Von 
Frey filaments (Stoelting, Wood Dale, IL, USA; mice: 0.07–2.00 g) according to the “up-and-down” 
method (Dixon, 1980). Mechanical threshold was assessed 3 times at each time point to yield a mean 
value, reported as paw withdrawal threshold (PWT). The development of mechano-allodynia is 
evidenced by a significant (P<0.05) reduction in mechanical mean PWT at forces that failed to elicit 
withdrawal responses on D0 before CCI or drug/vehicle treatment. 
 
 
 
5.5 Biochemical Assays  
 
5.5.2 Immunofluorescence assay 
For the study on A3AR agonists: mice received an i.p. injection of ketamine (11 mg/kg)/xylazine (1.1 
mg/kg) for deep anesthesia and were transcardially perfused with 1X PBS followed by 4% 
paraformaldehyde, pH 7.4. The lumbar portion of the spinal cord and lumbar DRGs (L4-L5) were 
harvested and post-fixed for 30 min at room temperature. Tissues were cryoprotected in a 30% 
sucrose solution at 4°C for 72 h and frozen in OCT. Samples were cryosectioned at 10 microns and 
blocked with 5% mouse, 5% goat, 1% BSA, 0.3 M glycine for 30 minutes at room temperature. A rat 
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anti-mouse CD4 (dilution 1:100; BioLegend) was incubated overnight at 4 °C in a humidity chamber. 
Following a series of rinses in PBS-T (Tween 20 0.25 %) and PBS, pH 7.4, the sections were 
incubated with an Alexa Fluor 568-conjugated goat anti-rat IgG (1:300; Life technologies). Prolong 
gold with DAPI was added and the slides were cover slipped. The images were acquired using 
Olympus FV1000 laser scanning confocal microscope. 
For the study on prokineticin system: 10 days after CCI L4-L5 spinal cord was dissected from 
transcardially perfused mice (PBS followed by 4% paraformaldehyde), post-fixed in 4% PFA for 24 
hours and cryoprotected in 30% sucrose solution. Tissues were embedded in cryostat medium, frozen 
and cut using a cryostat at 40 μm thick slices (free-floating). Prior to immunofluorescence staining 
sections were blocked with 3% normal donkey serum in 0.3% Triton X-100 for 30 min at room 
temperature and then incubated at 4°C for 48h with the following primary antibodies diluted in PBS-
0.3% Triton X-100: rabbit polyclonal anti-PROK2 (1:200, AbCam, Cambridge, UK), rabbit 
polyclonal anti -PKR2 (1:200, Alomone labs, Jerusalem, Israel), mouse polyclonal anti-glialfibrillary 
acidic protein (GFAP) (1:400) and mouse monoclonal anti-neuronal nuclei (NeuN) (1:400, 
Immunological Sciences, Italy). After washing, sections were incubated for 2h at room temperature 
with anti-species IgG secondary antibodies coupled to Alexa Fluor®-488 or 555 (1:200, 
Immunological Sciences). Nuclei were stained with DAPI (1:500, Sigma Aldrich). Possible non-
specific labeling of mouse secondary antibody was detected by using secondary antibody alone. The 
stained sections were examined at confocal laser scanning microscope (Leica SP5, Leica 
Microsystems, Wetzlar, Germany). 
 
 
5.6 Statistical analysis 
The data are expressed as mean ± SD for n animals and analysed by two-way repeated-measures 
ANOVA with Bonferroni post hoc test. Significant differences were defined as p < 0.05. GraphPad 
Prism 7 for Windows version 7.03. 
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